Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16628128,flow-rate,"The mobile phase was acetonitrile-water (70:30) at a flow-rate of 1.0 mL/min, and the derivatives were eluted at 13.1 and 15.5 minutes for paroxetine and desipramine, respectively, and detected at 567 nm.","Determination of paroxetine in human plasma by high-performance liquid chromatography using 7,7,8,8-tetracyanoquinodimethane as the derivatization reagent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628128/),[ml] / [min],1.0,3755,DB00715,Paroxetine
,16628128,detection limit,"Calibration curve was found linear over the range of 20-400 ng/mL, and the detection limit was 2 ng/mL at a signal-to-noise ratio of 3/1.","Determination of paroxetine in human plasma by high-performance liquid chromatography using 7,7,8,8-tetracyanoquinodimethane as the derivatization reagent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628128/),[ng] / [ml],2,3756,DB00715,Paroxetine
,16628128,signal-to-noise ratio,"Calibration curve was found linear over the range of 20-400 ng/mL, and the detection limit was 2 ng/mL at a signal-to-noise ratio of 3/1.","Determination of paroxetine in human plasma by high-performance liquid chromatography using 7,7,8,8-tetracyanoquinodimethane as the derivatization reagent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628128/),,3/1,3757,DB00715,Paroxetine
,16628128,Recoveries,Recoveries determined for 3 concentrations range between 81.3% and 88.1%.,"Determination of paroxetine in human plasma by high-performance liquid chromatography using 7,7,8,8-tetracyanoquinodimethane as the derivatization reagent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628128/),%,81.3,3758,DB00715,Paroxetine
,16628128,Recoveries,Recoveries determined for 3 concentrations range between 81.3% and 88.1%.,"Determination of paroxetine in human plasma by high-performance liquid chromatography using 7,7,8,8-tetracyanoquinodimethane as the derivatization reagent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628128/),%,88.1,3759,DB00715,Paroxetine
,17124578,peak plasma concentration (C(max)),"Compared with the placebo, terbinafine treatment significantly increased the peak plasma concentration (C(max)) of paroxetine, by 1.9-fold (6.4 +/- 2.4 versus 12.1 +/- 2.9 ng/ml, p < 0.001), and the area under the plasma concentration-time curve from zero to 48 h [AUC (0-48)] of paroxetine by 2.5-fold (127 +/- 67 vs 318 +/- 102 ng/ml, p < 0.001).",Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17124578/),[ng] / [ml],6.4,5419,DB00715,Paroxetine
,17124578,peak plasma concentration (C(max)),"Compared with the placebo, terbinafine treatment significantly increased the peak plasma concentration (C(max)) of paroxetine, by 1.9-fold (6.4 +/- 2.4 versus 12.1 +/- 2.9 ng/ml, p < 0.001), and the area under the plasma concentration-time curve from zero to 48 h [AUC (0-48)] of paroxetine by 2.5-fold (127 +/- 67 vs 318 +/- 102 ng/ml, p < 0.001).",Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17124578/),[ng] / [ml],12.1,5420,DB00715,Paroxetine
,17124578,area under the plasma concentration-time curve from zero to 48 h [AUC (0-48)],"Compared with the placebo, terbinafine treatment significantly increased the peak plasma concentration (C(max)) of paroxetine, by 1.9-fold (6.4 +/- 2.4 versus 12.1 +/- 2.9 ng/ml, p < 0.001), and the area under the plasma concentration-time curve from zero to 48 h [AUC (0-48)] of paroxetine by 2.5-fold (127 +/- 67 vs 318 +/- 102 ng/ml, p < 0.001).",Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17124578/),[ng] / [ml],127,5421,DB00715,Paroxetine
,17124578,area under the plasma concentration-time curve from zero to 48 h [AUC (0-48)],"Compared with the placebo, terbinafine treatment significantly increased the peak plasma concentration (C(max)) of paroxetine, by 1.9-fold (6.4 +/- 2.4 versus 12.1 +/- 2.9 ng/ml, p < 0.001), and the area under the plasma concentration-time curve from zero to 48 h [AUC (0-48)] of paroxetine by 2.5-fold (127 +/- 67 vs 318 +/- 102 ng/ml, p < 0.001).",Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17124578/),[ng] / [ml],318,5422,DB00715,Paroxetine
,17124578,Elimination half-life,"Elimination half-life differed significantly (15.3 +/- 2.4 vs 22.7 +/- 8.8 h, p < 0.05), although the magnitude of alteration (1.4-fold) was smaller than C(max )or AUC.",Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17124578/),h,15.3,5423,DB00715,Paroxetine
,17124578,Elimination half-life,"Elimination half-life differed significantly (15.3 +/- 2.4 vs 22.7 +/- 8.8 h, p < 0.05), although the magnitude of alteration (1.4-fold) was smaller than C(max )or AUC.",Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17124578/),h,22.7,5424,DB00715,Paroxetine
,9746264,recoveries,Their recoveries were around 90%.,Rapid simple high-performance liquid chromatographic determination of paroxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9746264/),%,90,6113,DB00715,Paroxetine
,9746264,detection limit,The detection limit was 0.2 ng/ml.,Rapid simple high-performance liquid chromatographic determination of paroxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9746264/),[ng] / [ml],0.2,6114,DB00715,Paroxetine
,26446141,exposure,Endoxifen exposure was ~3-fold higher during escitalopram co-administration than during paroxetine or fluoxetine co-administration (median 387 nM·h [range 159-637 nM·h] versus 99.2 nM·h [range 70.0-210 nM·h]; P = 0.012; Wilcoxon signed-rank test).,Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446141/),h·nM,387,7523,DB00715,Paroxetine
,26446141,exposure,Endoxifen exposure was ~3-fold higher during escitalopram co-administration than during paroxetine or fluoxetine co-administration (median 387 nM·h [range 159-637 nM·h] versus 99.2 nM·h [range 70.0-210 nM·h]; P = 0.012; Wilcoxon signed-rank test).,Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446141/),h·nM,99.2,7524,DB00715,Paroxetine
,1531951,steady-state concentrations,On a dose of 30 mg/day there was a 25-fold variation in steady-state concentrations (25 to 670 nmol/L).,Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531951/),[nM] / [l],25 to 670,13828,DB00715,Paroxetine
,10598311,half-life,"The half-life of fluoxetine and its active metabolite norfluoxetine is respectively 2 to 4 days and 7 to 15 days, more extended than other SSRIs (approximately 1 day).",[Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598311/),d,2 to 4,14164,DB00715,Paroxetine
,10598311,half-life,"The half-life of fluoxetine and its active metabolite norfluoxetine is respectively 2 to 4 days and 7 to 15 days, more extended than other SSRIs (approximately 1 day).",[Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598311/),d,7 to 15,14165,DB00715,Paroxetine
,10598311,half-life,"The half-life of fluoxetine and its active metabolite norfluoxetine is respectively 2 to 4 days and 7 to 15 days, more extended than other SSRIs (approximately 1 day).",[Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598311/),d,1,14166,DB00715,Paroxetine
,17803058,mlz,"The ionization was optimized using ESI(+) and selectivity was achieved by MS-MS analysis, mlz 330.0-->192.0 and m/ z 310-->148 for paroxetine and fluoxetine, respectively.",Determination of paroxetine in plasma by liquid chromatography coupled to tandem mass spectrometry for pharmacokinetic and bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803058/),,330.0,14930,DB00715,Paroxetine
,17803058,mlz,"The ionization was optimized using ESI(+) and selectivity was achieved by MS-MS analysis, mlz 330.0-->192.0 and m/ z 310-->148 for paroxetine and fluoxetine, respectively.",Determination of paroxetine in plasma by liquid chromatography coupled to tandem mass spectrometry for pharmacokinetic and bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803058/),,192.0,14931,DB00715,Paroxetine
,17803058,m/ z,"The ionization was optimized using ESI(+) and selectivity was achieved by MS-MS analysis, mlz 330.0-->192.0 and m/ z 310-->148 for paroxetine and fluoxetine, respectively.",Determination of paroxetine in plasma by liquid chromatography coupled to tandem mass spectrometry for pharmacokinetic and bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803058/),,310,14932,DB00715,Paroxetine
,17803058,m/ z,"The ionization was optimized using ESI(+) and selectivity was achieved by MS-MS analysis, mlz 330.0-->192.0 and m/ z 310-->148 for paroxetine and fluoxetine, respectively.",Determination of paroxetine in plasma by liquid chromatography coupled to tandem mass spectrometry for pharmacokinetic and bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803058/),,148,14933,DB00715,Paroxetine
,17803058,total run time,The method has a total run time of 1.5 min and was linear over a working range of 0.05-20 ng/mL and the lower limit of quantification was 0.05 ng/ mL.,Determination of paroxetine in plasma by liquid chromatography coupled to tandem mass spectrometry for pharmacokinetic and bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803058/),min,1.5,14934,DB00715,Paroxetine
,15788540,kinact,"We have predicted the pharmacokinetic consequences of CYP2D6 inactivation by paroxetine from in vitro inactivation kinetics (kinact 0.17 min(-1), unbound KI 0.315 microM), in vivo inhibitor concentrations, and an estimated CYP2D6 degradation half-life of 51 h, using a mathematical model of mechanism-based inhibition.",In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15788540/),1/[min],0.17,28928,DB00715,Paroxetine
,15788540,unbound KI,"We have predicted the pharmacokinetic consequences of CYP2D6 inactivation by paroxetine from in vitro inactivation kinetics (kinact 0.17 min(-1), unbound KI 0.315 microM), in vivo inhibitor concentrations, and an estimated CYP2D6 degradation half-life of 51 h, using a mathematical model of mechanism-based inhibition.",In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15788540/),μM,0.315,28929,DB00715,Paroxetine
,15788540,degradation half-life,"We have predicted the pharmacokinetic consequences of CYP2D6 inactivation by paroxetine from in vitro inactivation kinetics (kinact 0.17 min(-1), unbound KI 0.315 microM), in vivo inhibitor concentrations, and an estimated CYP2D6 degradation half-life of 51 h, using a mathematical model of mechanism-based inhibition.",In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15788540/),h,51,28930,DB00715,Paroxetine
,15788540,degradation half-life,Simulation of the sensitivities of these predictions to model inputs suggests a 2-fold underprediction of interaction magnitude when a CYP2D6 degradation half-life of 14 h (reported for rat CYP3A) is used.,In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15788540/),h,14,28931,DB00715,Paroxetine
,15701774,occupancy,The mACh receptor occupancy was estimated to be decreased from 0.22% to 0.020% by replacing paroxetine with fluvoxamine.,Improvement of dry mouth by replacing paroxetine with fluvoxamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15701774/),%,0.22,29064,DB00715,Paroxetine
,15701774,occupancy,The mACh receptor occupancy was estimated to be decreased from 0.22% to 0.020% by replacing paroxetine with fluvoxamine.,Improvement of dry mouth by replacing paroxetine with fluvoxamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15701774/),%,0.020,29065,DB00715,Paroxetine
,25559065,AUC0-36,"Study A: Geometric mean AUC0-36 for BCQB alone and co-administered with paroxetine were 474.3 and 631.3pgh/ml, respectively.",Study of pharmacokinetic interaction of paroxetine and roxithromycin on bencycloquidium bromide in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25559065/),[pgh] / [ml],474.3,33024,DB00715,Paroxetine
,25559065,AUC0-36,"Study A: Geometric mean AUC0-36 for BCQB alone and co-administered with paroxetine were 474.3 and 631.3pgh/ml, respectively.",Study of pharmacokinetic interaction of paroxetine and roxithromycin on bencycloquidium bromide in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25559065/),[pgh] / [ml],631.3,33025,DB00715,Paroxetine
,25559065,Cmax,Geometric mean Cmax were 187.0 and 181.2pg/ml.,Study of pharmacokinetic interaction of paroxetine and roxithromycin on bencycloquidium bromide in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25559065/),[pg] / [ml],187.0,33026,DB00715,Paroxetine
,25559065,Cmax,Geometric mean Cmax were 187.0 and 181.2pg/ml.,Study of pharmacokinetic interaction of paroxetine and roxithromycin on bencycloquidium bromide in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25559065/),[pg] / [ml],181.2,33027,DB00715,Paroxetine
,7992822,elimination half-lives,"The selective serotonin reuptake inhibitors (SSRIs)--paroxetine, sertraline, and fluvoxamine--have elimination half-lives of 15-26 hours.",Pharmacokinetics of the newer antidepressants: clinical relevance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7992822/),h,15-26,43464,DB00715,Paroxetine
,7992822,half-life,"The extended half-life of fluoxetine (4-6 days) and its active metabolite, norfluoxetine (4-16 days), results in an extended time to steady-state and a prolonged washout period when dosing is discontinued.",Pharmacokinetics of the newer antidepressants: clinical relevance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7992822/),d,4-6,43465,DB00715,Paroxetine
,7992822,half-life,"The extended half-life of fluoxetine (4-6 days) and its active metabolite, norfluoxetine (4-16 days), results in an extended time to steady-state and a prolonged washout period when dosing is discontinued.",Pharmacokinetics of the newer antidepressants: clinical relevance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7992822/),d,4-16,43466,DB00715,Paroxetine
,7992822,half-lives,"Venlafaxine and nefazodone have short half-lives, 2-5 hours, and are dosed > or = 2 times daily.",Pharmacokinetics of the newer antidepressants: clinical relevance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7992822/),h,2-5,43467,DB00715,Paroxetine
,1839532,trough drug concentration at steady state (CSSmin),"Dose-corrected, trough drug concentration at steady state (CSSmin) and dose-corrected AUC24h were significantly higher in the patients with liver diseases than in the control subjects [3.4 vs 1.5 ng.",Pharmacokinetics of paroxetine in patients with cirrhosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1839532/),ng,3.4,46531,DB00715,Paroxetine
,1839532,dose-corrected AUC24h,"Dose-corrected, trough drug concentration at steady state (CSSmin) and dose-corrected AUC24h were significantly higher in the patients with liver diseases than in the control subjects [3.4 vs 1.5 ng.",Pharmacokinetics of paroxetine in patients with cirrhosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1839532/),ng,1.5,46532,DB00715,Paroxetine
,1839532,elimination t1/2,"The elimination t1/2 was prolonged [83 vs 36 h], but the difference was not statistically significant, and the cirrhotic patients were still able to clear almost all the paroxetine by metabolism.",Pharmacokinetics of paroxetine in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1839532/),h,83,46533,DB00715,Paroxetine
,1839532,elimination t1/2,"The elimination t1/2 was prolonged [83 vs 36 h], but the difference was not statistically significant, and the cirrhotic patients were still able to clear almost all the paroxetine by metabolism.",Pharmacokinetics of paroxetine in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1839532/),h,36,46534,DB00715,Paroxetine
less,7834966,t1/2,"Among the SSRIs, there are a range of t1/2 values for the parent drugs, from relatively short t1/2 values of less than 24 hours (paroxetine, fluvoxamine) to among the longest found (e.g. 2 days for fluoxetine).",Pharmacokinetic optimisation of therapy with newer antidepressants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),h,24,56611,DB00715,Paroxetine
,7834966,t1/2,"Among the SSRIs, there are a range of t1/2 values for the parent drugs, from relatively short t1/2 values of less than 24 hours (paroxetine, fluvoxamine) to among the longest found (e.g. 2 days for fluoxetine).",Pharmacokinetic optimisation of therapy with newer antidepressants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),d,2,56612,DB00715,Paroxetine
,7834966,tmax,"All 3 of the structurally unique newer antidepressants [amfebutamone (bupropion), viloxazine venlafaxine] have relatively short tmax values (1 to 2 hours), which may relate to the early onset of adverse effects.",Pharmacokinetic optimisation of therapy with newer antidepressants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),h,1 to 2,56613,DB00715,Paroxetine
,12405865,bioavailability,Methadone has a mean bioavailability of around 75% (range 36-100%).,Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),%,75,57243,DB00715,Paroxetine
,12405865,free fraction,"Its mean free fraction is around 13%, with a 4-fold interindividual variation.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),%,13,57244,DB00715,Paroxetine
,12405865,volume of distribution,Its volume of distribution is about 4 L/kg (range 2-13 L/kg).,Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),[l] / [kg],4,57245,DB00715,Paroxetine
,12405865,Total body clearance,"Total body clearance is about 0.095 L/min, with wide interindividual variation (range 0.02-2 L/min).",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),[l] / [min],0.095,57246,DB00715,Paroxetine
,12405865,elimination half-life,"Plasma concentrations of methadone decrease in a biexponential manner, with a mean value of around 22 hours (range 5-130 hours) for elimination half-life.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),h,22,57247,DB00715,Paroxetine
,12405865,elimination half-life,"Plasma concentrations of methadone decrease in a biexponential manner, with a mean value of around 22 hours (range 5-130 hours) for elimination half-life.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),h,5,57248,DB00715,Paroxetine
,12405865,trough plasma concentrations,"In the case of non-response trough plasma concentrations of 400 microg/L for (R,S)-methadone or 250 microg/L for (R)-methadone might be used as target values.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),[μg] / [l],400,57249,DB00715,Paroxetine
,12405865,trough plasma concentrations,"In the case of non-response trough plasma concentrations of 400 microg/L for (R,S)-methadone or 250 microg/L for (R)-methadone might be used as target values.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),[μg] / [l],250,57250,DB00715,Paroxetine
,20006083,flow rate,"The derivatized plasma samples were injected into the HPLC system where an on-line sample clean up was achieved on the pre-treatment column (Co-sense Shim-pack MAYI-ODS) with a washing mobile phase (acetonitrile:2% acetic acid; 40:60, v/v) at a flow rate of 5mLmin(-1) for 1min.",A highly sensitive HPLC method with automated on-line sample pre-treatment and fluorescence detection for determination of reboxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20006083/),1/[mlmin],5,59116,DB00715,Paroxetine
,20006083,flow rate,"After an automated on-line column switching to the analytical Hypersil phenyl 120A column (250mmx4.6mm, 5microm), the separation of the derivatized RBX and PXT was performed using a mobile phase consisting of sodium acetate buffer (pH 3.5):tetrahydrofuran:acetonitrile (55:35:10, v/v/v) at a flow rate of 2.0mLmin(-1).",A highly sensitive HPLC method with automated on-line sample pre-treatment and fluorescence detection for determination of reboxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20006083/),1/[mlmin],2.0,59117,DB00715,Paroxetine
,20006083,recovery,"The accuracy of the method proved as the mean recovery values were 100.11+/-2.24% and 100.99+/-2.98% for the intra- and inter-day assay runs, respectively.",A highly sensitive HPLC method with automated on-line sample pre-treatment and fluorescence detection for determination of reboxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20006083/),%,100.11,59118,DB00715,Paroxetine
,20006083,recovery,"The accuracy of the method proved as the mean recovery values were 100.11+/-2.24% and 100.99+/-2.98% for the intra- and inter-day assay runs, respectively.",A highly sensitive HPLC method with automated on-line sample pre-treatment and fluorescence detection for determination of reboxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20006083/),%,100.99,59119,DB00715,Paroxetine
,10741632,area under the plasma concentration-time curve extrapolated to infinity (AUC),"Paroxetine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC) of (R)- and (S)-metoprolol significantly (169 to 1,340 ng x h/mL [P < .001] and 279 to 1,418 ng x h/mL [P < .001], respectively), with an approximately twofold increase in both maximum plasma concentration and terminal elimination half-life.",Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741632/),[h·ng] / [ml],169,60213,DB00715,Paroxetine
,10741632,area under the plasma concentration-time curve extrapolated to infinity (AUC),"Paroxetine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC) of (R)- and (S)-metoprolol significantly (169 to 1,340 ng x h/mL [P < .001] and 279 to 1,418 ng x h/mL [P < .001], respectively), with an approximately twofold increase in both maximum plasma concentration and terminal elimination half-life.",Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741632/),[h·ng] / [ml],1,60214,DB00715,Paroxetine
,10741632,area under the plasma concentration-time curve extrapolated to infinity (AUC),"Paroxetine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC) of (R)- and (S)-metoprolol significantly (169 to 1,340 ng x h/mL [P < .001] and 279 to 1,418 ng x h/mL [P < .001], respectively), with an approximately twofold increase in both maximum plasma concentration and terminal elimination half-life.",Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741632/),[h·ng] / [ml],279 to,60215,DB00715,Paroxetine
,10741632,AUC ratio,"Furthermore, the (S)/(R) AUC ratio was significantly decreased, from 1.72 to 1.07 (P < .001).",Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741632/),,1.72,60216,DB00715,Paroxetine
,10741632,AUC ratio,"Furthermore, the (S)/(R) AUC ratio was significantly decreased, from 1.72 to 1.07 (P < .001).",Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741632/),,1.07,60217,DB00715,Paroxetine
,10741632,MR,"The mean metoprolol MR was significantly increased, from 0.17 to 5.69 (P < .05).",Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741632/),,0.17,60218,DB00715,Paroxetine
,10741632,MR,"The mean metoprolol MR was significantly increased, from 0.17 to 5.69 (P < .05).",Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741632/),,5.69,60219,DB00715,Paroxetine
,10674711,half-lives,"Under steady-state concentrations, their half-lives range between 1 and 4 days for fluoxetine (7 and 15 days for norfluoxetine) and between 21 (paroxetine) and 36 (citalopram) hr for the other SSRIs.",Pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674711/),d,1 and 4,62758,DB00715,Paroxetine
,10674711,half-lives,"Under steady-state concentrations, their half-lives range between 1 and 4 days for fluoxetine (7 and 15 days for norfluoxetine) and between 21 (paroxetine) and 36 (citalopram) hr for the other SSRIs.",Pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674711/),d,7 and 15,62759,DB00715,Paroxetine
,10674711,half-lives,"Under steady-state concentrations, their half-lives range between 1 and 4 days for fluoxetine (7 and 15 days for norfluoxetine) and between 21 (paroxetine) and 36 (citalopram) hr for the other SSRIs.",Pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674711/),h,21,62760,DB00715,Paroxetine
,10674711,half-lives,"Under steady-state concentrations, their half-lives range between 1 and 4 days for fluoxetine (7 and 15 days for norfluoxetine) and between 21 (paroxetine) and 36 (citalopram) hr for the other SSRIs.",Pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674711/),h,36,62761,DB00715,Paroxetine
,26350273,Cmax,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[ng] / [ml],16.8,65144,DB00715,Paroxetine
,26350273,Cmax,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[ng] / [ml],15.9,65145,DB00715,Paroxetine
,26350273,t½,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[ng] / [ml],16.8,65146,DB00715,Paroxetine
,26350273,t½,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[ng] / [ml],15.9,65147,DB00715,Paroxetine
,26350273,t½,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),h,8.5,65148,DB00715,Paroxetine
,26350273,Tmax,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),h,8.4,65149,DB00715,Paroxetine
,26350273,Tmax,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),h,18.0,65150,DB00715,Paroxetine
,26350273,AUC0-t,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],342.9,65151,DB00715,Paroxetine
,26350273,AUC0-∞,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],325.3,65152,DB00715,Paroxetine
,26350273,AUC0-∞,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],346.3,65153,DB00715,Paroxetine
,26350273,AUC0-∞,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],328.5,65154,DB00715,Paroxetine
,26350273,AUC0-t,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],0.64,65155,DB00715,Paroxetine
,26350273,AUC0-t,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],3.8,65156,DB00715,Paroxetine
,26350273,Cmax,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],3.8,65157,DB00715,Paroxetine
,26350273,Cmax,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[ng] / [ml],0.06,65158,DB00715,Paroxetine
,26350273,Cmax,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[ng] / [ml],0.19,65159,DB00715,Paroxetine
,26350273,Tmax,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),h,18.0,65160,DB00715,Paroxetine
,26350273,Tmax,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),h,16.1,65161,DB00715,Paroxetine
,18250057,C(max),"The main pharmacokinetics parameters of paroxetine were: C(max)64.74-/+18.43 ng/ml, T(max)5.64-/+1.84 h, t(1/2) 20.03-/+5.33 h, AUC(0-120) 976.47-/+309.49 ng.h/ml, and AUC(0-inf) 1086.75-/+376.54 ng.h/ml.",[Pharmacokinetics of paroxetine tablet in healthy Chinese volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18250057/),[ng] / [ml],64.74,66484,DB00715,Paroxetine
,18250057,T(max),"The main pharmacokinetics parameters of paroxetine were: C(max)64.74-/+18.43 ng/ml, T(max)5.64-/+1.84 h, t(1/2) 20.03-/+5.33 h, AUC(0-120) 976.47-/+309.49 ng.h/ml, and AUC(0-inf) 1086.75-/+376.54 ng.h/ml.",[Pharmacokinetics of paroxetine tablet in healthy Chinese volunteers]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18250057/),h,5.64,66485,DB00715,Paroxetine
,18250057,t(1/2),"The main pharmacokinetics parameters of paroxetine were: C(max)64.74-/+18.43 ng/ml, T(max)5.64-/+1.84 h, t(1/2) 20.03-/+5.33 h, AUC(0-120) 976.47-/+309.49 ng.h/ml, and AUC(0-inf) 1086.75-/+376.54 ng.h/ml.",[Pharmacokinetics of paroxetine tablet in healthy Chinese volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18250057/),h,20.03,66486,DB00715,Paroxetine
,18250057,AUC(0-120),"The main pharmacokinetics parameters of paroxetine were: C(max)64.74-/+18.43 ng/ml, T(max)5.64-/+1.84 h, t(1/2) 20.03-/+5.33 h, AUC(0-120) 976.47-/+309.49 ng.h/ml, and AUC(0-inf) 1086.75-/+376.54 ng.h/ml.",[Pharmacokinetics of paroxetine tablet in healthy Chinese volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18250057/),[h·ng] / [ml],976.47,66487,DB00715,Paroxetine
,18250057,AUC(0-inf),"The main pharmacokinetics parameters of paroxetine were: C(max)64.74-/+18.43 ng/ml, T(max)5.64-/+1.84 h, t(1/2) 20.03-/+5.33 h, AUC(0-120) 976.47-/+309.49 ng.h/ml, and AUC(0-inf) 1086.75-/+376.54 ng.h/ml.",[Pharmacokinetics of paroxetine tablet in healthy Chinese volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18250057/),[h·ng] / [ml],1086.75,66488,DB00715,Paroxetine
,10824636,AUC,The AUC of paroxetine in subjects who were homozygous for CYP2D6*10B (666.4 +/- 169.4 ng/mL x h) was significantly greater than that of subjects who were homozygous for the wild type (194.5 +/- 55.9 ng/mL x h).,Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824636/),[ng] / [h·ml],666.4,73233,DB00715,Paroxetine
,10824636,AUC,The AUC of paroxetine in subjects who were homozygous for CYP2D6*10B (666.4 +/- 169.4 ng/mL x h) was significantly greater than that of subjects who were homozygous for the wild type (194.5 +/- 55.9 ng/mL x h).,Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824636/),[ng] / [h·ml],194.5,73234,DB00715,Paroxetine
,10824636,AUC,"Unexpectedly, the average AUC of subjects who were heterozygous for CYP2D6*10B was greater with wide variation (789.8 +/- 816.9 ng/mL x h) than that of subjects who were homozygous CYP2D6*10B/*10B mainly because of two atypical subjects whose metoprolol MR was not associated with the CYP2D6*10B genotype and who showed greater AUC and lower oral clearance than subjects with homozygous CYP2D6*10B.",Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824636/),[ng] / [h·ml],789.8,73235,DB00715,Paroxetine
,27936523,lag time,"For both single- and multiple-dose regimens, a lag time of ~ 4 hours was observed before the absorption of paroxetine CR tablet with a t<sub>max</sub> of ~ 7 - 9 hours.",Single- and multiple-dose pharmacokinetics and tolerability of a paroxetine controlled-release tablet in healthy Chinese subjects . ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27936523/),h,4,77552,DB00715,Paroxetine
,27936523,t<sub>max</sub>,"For both single- and multiple-dose regimens, a lag time of ~ 4 hours was observed before the absorption of paroxetine CR tablet with a t<sub>max</sub> of ~ 7 - 9 hours.",Single- and multiple-dose pharmacokinetics and tolerability of a paroxetine controlled-release tablet in healthy Chinese subjects . ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27936523/),h,7 - 9,77553,DB00715,Paroxetine
,27936523,C<sub>max</sub>,"From single- to multiple-dose regimens, the mean C<sub>max</sub> increased from 7.08 to 36.95 ng/mL, the mean AUC<sub>0-24h</sub> increased from 100.91 to 706.75 h×ng/mL, and the mean t<sub>1/2</sub> increased from 12.3 to 83.6 hours (all p < 0.05).",Single- and multiple-dose pharmacokinetics and tolerability of a paroxetine controlled-release tablet in healthy Chinese subjects . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27936523/),[ng] / [ml],7.08 to 36.95,77554,DB00715,Paroxetine
,27936523,AUC<sub>0-24h<,"From single- to multiple-dose regimens, the mean C<sub>max</sub> increased from 7.08 to 36.95 ng/mL, the mean AUC<sub>0-24h</sub> increased from 100.91 to 706.75 h×ng/mL, and the mean t<sub>1/2</sub> increased from 12.3 to 83.6 hours (all p < 0.05).",Single- and multiple-dose pharmacokinetics and tolerability of a paroxetine controlled-release tablet in healthy Chinese subjects . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27936523/),[h·ng] / [ml],100.91 to 706.75,77555,DB00715,Paroxetine
,27936523,t<sub>1/2</sub>,"From single- to multiple-dose regimens, the mean C<sub>max</sub> increased from 7.08 to 36.95 ng/mL, the mean AUC<sub>0-24h</sub> increased from 100.91 to 706.75 h×ng/mL, and the mean t<sub>1/2</sub> increased from 12.3 to 83.6 hours (all p < 0.05).",Single- and multiple-dose pharmacokinetics and tolerability of a paroxetine controlled-release tablet in healthy Chinese subjects . ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27936523/),h,12.3 to 83.6,77556,DB00715,Paroxetine
,27936523,accumulation factor,"Paroxetine CR tablet is absorbed with a delay of ~ 4 hours after oral administration, and the accumulation factor is ~ 9 at steady state.",Single- and multiple-dose pharmacokinetics and tolerability of a paroxetine controlled-release tablet in healthy Chinese subjects . ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27936523/),,9,77557,DB00715,Paroxetine
,26733750,Cmax,"Cmax increased from 221.26±94.93 to 372.53±128.28 ng/mL, while AUC0-t and AUC0-∞ also increased from 1151.19±686.52 to 6452.37±3388.76 ng*h/mL, and from 1229.15±751.04 to 7111.74±4195.17 ng*h/mL respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[ng] / [ml],221.26,81021,DB00715,Paroxetine
,26733750,Cmax,"Cmax increased from 221.26±94.93 to 372.53±128.28 ng/mL, while AUC0-t and AUC0-∞ also increased from 1151.19±686.52 to 6452.37±3388.76 ng*h/mL, and from 1229.15±751.04 to 7111.74±4195.17 ng*h/mL respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[ng] / [ml],372.53,81022,DB00715,Paroxetine
,26733750,AUC0-t,"Cmax increased from 221.26±94.93 to 372.53±128.28 ng/mL, while AUC0-t and AUC0-∞ also increased from 1151.19±686.52 to 6452.37±3388.76 ng*h/mL, and from 1229.15±751.04 to 7111.74±4195.17 ng*h/mL respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[h·ng] / [ml],1151.19,81023,DB00715,Paroxetine
,26733750,AUC0-∞,"Cmax increased from 221.26±94.93 to 372.53±128.28 ng/mL, while AUC0-t and AUC0-∞ also increased from 1151.19±686.52 to 6452.37±3388.76 ng*h/mL, and from 1229.15±751.04 to 7111.74±4195.17 ng*h/mL respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[h·ng] / [ml],6452.37,81024,DB00715,Paroxetine
,26733750,AUC0-∞,"Cmax increased from 221.26±94.93 to 372.53±128.28 ng/mL, while AUC0-t and AUC0-∞ also increased from 1151.19±686.52 to 6452.37±3388.76 ng*h/mL, and from 1229.15±751.04 to 7111.74±4195.17 ng*h/mL respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[h·ng] / [ml],1229.15,81025,DB00715,Paroxetine
,26733750,AUC0-∞,"Cmax increased from 221.26±94.93 to 372.53±128.28 ng/mL, while AUC0-t and AUC0-∞ also increased from 1151.19±686.52 to 6452.37±3388.76 ng*h/mL, and from 1229.15±751.04 to 7111.74±4195.17 ng*h/mL respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[h·ng] / [ml],7111.74,81026,DB00715,Paroxetine
,26733750,Cmax,"The main metabolite pharmacokinetics was also influenced by paroxetine intake, namely Cmax, AUC0-t and AUC0-∞ decreased from 688.76±270.27 to 131.01±100.43 ng*h/mL, and from 4810.93±845.06 to 2606.04±923.88 and from 4928.55±853.25 to 3029.82 ±941.84 respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[h·ng] / [ml],688.76,81027,DB00715,Paroxetine
,26733750,AUC0-t,"The main metabolite pharmacokinetics was also influenced by paroxetine intake, namely Cmax, AUC0-t and AUC0-∞ decreased from 688.76±270.27 to 131.01±100.43 ng*h/mL, and from 4810.93±845.06 to 2606.04±923.88 and from 4928.55±853.25 to 3029.82 ±941.84 respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[h·ng] / [ml],131.01,81028,DB00715,Paroxetine
,26733750,AUC0-t,"The main metabolite pharmacokinetics was also influenced by paroxetine intake, namely Cmax, AUC0-t and AUC0-∞ decreased from 688.76±270.27 to 131.01±100.43 ng*h/mL, and from 4810.93±845.06 to 2606.04±923.88 and from 4928.55±853.25 to 3029.82 ±941.84 respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[h·ng] / [ml],4810.93,81029,DB00715,Paroxetine
,26733750,AUC0-t,"The main metabolite pharmacokinetics was also influenced by paroxetine intake, namely Cmax, AUC0-t and AUC0-∞ decreased from 688.76±270.27 to 131.01±100.43 ng*h/mL, and from 4810.93±845.06 to 2606.04±923.88 and from 4928.55±853.25 to 3029.82 ±941.84 respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[h·ng] / [ml],2606.04,81030,DB00715,Paroxetine
,26733750,AUC0-t,"The main metabolite pharmacokinetics was also influenced by paroxetine intake, namely Cmax, AUC0-t and AUC0-∞ decreased from 688.76±270.27 to 131.01±100.43 ng*h/mL, and from 4810.93±845.06 to 2606.04±923.88 and from 4928.55±853.25 to 3029.82 ±941.84 respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[h·ng] / [ml],4928.55,81031,DB00715,Paroxetine
,26733750,AUC0-∞,"The main metabolite pharmacokinetics was also influenced by paroxetine intake, namely Cmax, AUC0-t and AUC0-∞ decreased from 688.76±270.27 to 131.01±100.43 ng*h/mL, and from 4810.93±845.06 to 2606.04±923.88 and from 4928.55±853.25 to 3029.82 ±941.84 respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[h·ng] / [ml],2606.04,81032,DB00715,Paroxetine
,26733750,AUC0-∞,"The main metabolite pharmacokinetics was also influenced by paroxetine intake, namely Cmax, AUC0-t and AUC0-∞ decreased from 688.76±270.27 to 131.01±100.43 ng*h/mL, and from 4810.93±845.06 to 2606.04±923.88 and from 4928.55±853.25 to 3029.82 ±941.84 respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[h·ng] / [ml],4928.55,81033,DB00715,Paroxetine
,26733750,AUC0-∞,"The main metabolite pharmacokinetics was also influenced by paroxetine intake, namely Cmax, AUC0-t and AUC0-∞ decreased from 688.76±270.27 to 131.01±100.43 ng*h/mL, and from 4810.93±845.06 to 2606.04±923.88 and from 4928.55±853.25 to 3029.82 ±941.84 respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[h·ng] / [ml],3029.82,81034,DB00715,Paroxetine
,19912165,half-life,The in vivo half-life predicted for timolol was 3.7 hr.,Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),h,3.7,82486,DB00715,Paroxetine
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,1.4,82487,DB00715,Paroxetine
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,2.0,82488,DB00715,Paroxetine
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,3.5,82489,DB00715,Paroxetine
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,21,82490,DB00715,Paroxetine
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,20,82491,DB00715,Paroxetine
,19912165,IC(50),"In human cryo-preserved hepatocytes, the IC(50) values for fluoxetine, paroxetine and fluvoxamine were 0.7, 0.5 and 5.9 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,0.7,82492,DB00715,Paroxetine
,19912165,IC(50),"In human cryo-preserved hepatocytes, the IC(50) values for fluoxetine, paroxetine and fluvoxamine were 0.7, 0.5 and 5.9 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,0.5,82493,DB00715,Paroxetine
,19912165,IC(50),"In human cryo-preserved hepatocytes, the IC(50) values for fluoxetine, paroxetine and fluvoxamine were 0.7, 0.5 and 5.9 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,5.9,82494,DB00715,Paroxetine
,24845234,peak plasma concentrations (Cmax ),Pretreatment with paroxetine increased the mean peak plasma concentrations (Cmax ) for unchanged nebivolol (1·78 ± 1·17 vs. 4·24 ± 1·67 ng/mL) and for its active metabolite (0·58 ± 0·21 vs. 0·79 ± 0·24 ng/mL) compared to nebivolol alone.,A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),[ng] / [ml],1·78,88983,DB00715,Paroxetine
,24845234,peak plasma concentrations (Cmax ),Pretreatment with paroxetine increased the mean peak plasma concentrations (Cmax ) for unchanged nebivolol (1·78 ± 1·17 vs. 4·24 ± 1·67 ng/mL) and for its active metabolite (0·58 ± 0·21 vs. 0·79 ± 0·24 ng/mL) compared to nebivolol alone.,A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),[ng] / [ml],4·24,88984,DB00715,Paroxetine
,24845234,peak plasma concentrations (Cmax ),Pretreatment with paroxetine increased the mean peak plasma concentrations (Cmax ) for unchanged nebivolol (1·78 ± 1·17 vs. 4·24 ± 1·67 ng/mL) and for its active metabolite (0·58 ± 0·21 vs. 0·79 ± 0·24 ng/mL) compared to nebivolol alone.,A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),[ng] / [ml],0·58,88985,DB00715,Paroxetine
,24845234,peak plasma concentrations (Cmax ),Pretreatment with paroxetine increased the mean peak plasma concentrations (Cmax ) for unchanged nebivolol (1·78 ± 1·17 vs. 4·24 ± 1·67 ng/mL) and for its active metabolite (0·58 ± 0·21 vs. 0·79 ± 0·24 ng/mL) compared to nebivolol alone.,A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),[ng] / [ml],0·79,88986,DB00715,Paroxetine
,24845234,time (tmax ) to reach Cmax,"The time (tmax ) to reach Cmax was 1·37 ± 0·88 (h) and 3·11 ± 1·76 (h) for the parent compound and its active metabolite after nebivolol administered alone and 3·96 ± 1·76 (h), respectively, 7·33 ± 7·84 (h) after pretreatment with paroxetine.",A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),h,1·37,88987,DB00715,Paroxetine
,24845234,time (tmax ) to reach Cmax,"The time (tmax ) to reach Cmax was 1·37 ± 0·88 (h) and 3·11 ± 1·76 (h) for the parent compound and its active metabolite after nebivolol administered alone and 3·96 ± 1·76 (h), respectively, 7·33 ± 7·84 (h) after pretreatment with paroxetine.",A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),h,3·11,88988,DB00715,Paroxetine
,24845234,time (tmax ) to reach Cmax,"The time (tmax ) to reach Cmax was 1·37 ± 0·88 (h) and 3·11 ± 1·76 (h) for the parent compound and its active metabolite after nebivolol administered alone and 3·96 ± 1·76 (h), respectively, 7·33 ± 7·84 (h) after pretreatment with paroxetine.",A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),h,3·96,88989,DB00715,Paroxetine
,24845234,time (tmax ) to reach Cmax,"The time (tmax ) to reach Cmax was 1·37 ± 0·88 (h) and 3·11 ± 1·76 (h) for the parent compound and its active metabolite after nebivolol administered alone and 3·96 ± 1·76 (h), respectively, 7·33 ± 7·84 (h) after pretreatment with paroxetine.",A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),h,7·33,88990,DB00715,Paroxetine
,24845234,total areas under the curve (AUC0-∞ ),"Also, the total areas under the curve (AUC0-∞ ) were significantly increased from 17·26 ± 43·06 to 106·20 ± 65·56 h ng/mL for nebivolol unchanged and 13·03 ± 11·29 to 74·56 ± 88·77 h ng/mL for its hydroxylated metabolite, before and after paroxetine intake.",A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),[h·ng] / [ml],17·26,88991,DB00715,Paroxetine
,24845234,total areas under the curve (AUC0-∞ ),"Also, the total areas under the curve (AUC0-∞ ) were significantly increased from 17·26 ± 43·06 to 106·20 ± 65·56 h ng/mL for nebivolol unchanged and 13·03 ± 11·29 to 74·56 ± 88·77 h ng/mL for its hydroxylated metabolite, before and after paroxetine intake.",A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),[h·ng] / [ml],106·20,88992,DB00715,Paroxetine
,24845234,total areas under the curve (AUC0-∞ ),"Also, the total areas under the curve (AUC0-∞ ) were significantly increased from 17·26 ± 43·06 to 106·20 ± 65·56 h ng/mL for nebivolol unchanged and 13·03 ± 11·29 to 74·56 ± 88·77 h ng/mL for its hydroxylated metabolite, before and after paroxetine intake.",A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),[h·ng] / [ml],13·03,88993,DB00715,Paroxetine
,24845234,total areas under the curve (AUC0-∞ ),"Also, the total areas under the curve (AUC0-∞ ) were significantly increased from 17·26 ± 43·06 to 106·20 ± 65·56 h ng/mL for nebivolol unchanged and 13·03 ± 11·29 to 74·56 ± 88·77 h ng/mL for its hydroxylated metabolite, before and after paroxetine intake.",A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),[h·ng] / [ml],74·56,88994,DB00715,Paroxetine
,1531950,area under the plasma concentration-time curve (AUC),"The median area under the plasma concentration-time curve (AUC) after the first paroxetine dose was about seven times higher in poor metabolizers than in extensive metabolizers (3910 versus 550 nmol.hr/L), whereas at steady state the median AUCss tau interphenotype difference was only twofold (4410 versus 2550 nmol.hr/L).",The relationship between paroxetine and the sparteine oxidation polymorphism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531950/),[h·nM] / [l],3910,90140,DB00715,Paroxetine
,1531950,area under the plasma concentration-time curve (AUC),"The median area under the plasma concentration-time curve (AUC) after the first paroxetine dose was about seven times higher in poor metabolizers than in extensive metabolizers (3910 versus 550 nmol.hr/L), whereas at steady state the median AUCss tau interphenotype difference was only twofold (4410 versus 2550 nmol.hr/L).",The relationship between paroxetine and the sparteine oxidation polymorphism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531950/),[h·nM] / [l],550,90141,DB00715,Paroxetine
,1531950,AUCss,"The median area under the plasma concentration-time curve (AUC) after the first paroxetine dose was about seven times higher in poor metabolizers than in extensive metabolizers (3910 versus 550 nmol.hr/L), whereas at steady state the median AUCss tau interphenotype difference was only twofold (4410 versus 2550 nmol.hr/L).",The relationship between paroxetine and the sparteine oxidation polymorphism. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531950/),[h·nM] / [l],4410,90142,DB00715,Paroxetine
,1531950,AUCss,"The median area under the plasma concentration-time curve (AUC) after the first paroxetine dose was about seven times higher in poor metabolizers than in extensive metabolizers (3910 versus 550 nmol.hr/L), whereas at steady state the median AUCss tau interphenotype difference was only twofold (4410 versus 2550 nmol.hr/L).",The relationship between paroxetine and the sparteine oxidation polymorphism. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531950/),[h·nM] / [l],2550,90143,DB00715,Paroxetine
,1531950,Plasma half-life,"Plasma half-life and steady-state plasma concentration were significantly longer and higher, respectively, in poor metabolizers than in extensive metabolizers (41 versus 16 hours and 151 versus 81 nmol/L).",The relationship between paroxetine and the sparteine oxidation polymorphism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531950/),h,41,90144,DB00715,Paroxetine
,1531950,Plasma half-life,"Plasma half-life and steady-state plasma concentration were significantly longer and higher, respectively, in poor metabolizers than in extensive metabolizers (41 versus 16 hours and 151 versus 81 nmol/L).",The relationship between paroxetine and the sparteine oxidation polymorphism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531950/),h,16,90145,DB00715,Paroxetine
,1531950,steady-state plasma concentration,"Plasma half-life and steady-state plasma concentration were significantly longer and higher, respectively, in poor metabolizers than in extensive metabolizers (41 versus 16 hours and 151 versus 81 nmol/L).",The relationship between paroxetine and the sparteine oxidation polymorphism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531950/),[nM] / [l],151,90146,DB00715,Paroxetine
,1531950,steady-state plasma concentration,"Plasma half-life and steady-state plasma concentration were significantly longer and higher, respectively, in poor metabolizers than in extensive metabolizers (41 versus 16 hours and 151 versus 81 nmol/L).",The relationship between paroxetine and the sparteine oxidation polymorphism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531950/),[nM] / [l],81,90147,DB00715,Paroxetine
,1531950,metabolic ratio (MR,"Sparteine metabolic ratio (MR = 12 hour urinary ratio of sparteine/dehydrosparteine), increased during treatment with paroxetine in subjects who were extensive metabolizers, and after 14 days treatment two extensive metabolizers were phenotyped as poor metabolizers and the remaining extensive metabolizers were changed into extremely slow extensive metabolizers with sparteine MRs of 5.7 to 16.5.",The relationship between paroxetine and the sparteine oxidation polymorphism. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531950/),,12,90148,DB00715,Paroxetine
,1531950,MRs,"Sparteine metabolic ratio (MR = 12 hour urinary ratio of sparteine/dehydrosparteine), increased during treatment with paroxetine in subjects who were extensive metabolizers, and after 14 days treatment two extensive metabolizers were phenotyped as poor metabolizers and the remaining extensive metabolizers were changed into extremely slow extensive metabolizers with sparteine MRs of 5.7 to 16.5.",The relationship between paroxetine and the sparteine oxidation polymorphism. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531950/),,5.7 to 16.5,90149,DB00715,Paroxetine
,10417489,M/PAUC,The mean M/PAUC was 0.39 (range 0.32-0.51).,Paroxetine in human milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10417489/),,0.39,92292,DB00715,Paroxetine
,10417489,M/P,The predicted M/P was 0.22.,Paroxetine in human milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10417489/),,0.22,92293,DB00715,Paroxetine
,10417489,M/P,The mean M/P was 0.96 (range 0.31-3.33) and did not differ between fore and hind milk.,Paroxetine in human milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10417489/),,0.96,92294,DB00715,Paroxetine
,17981422,total chromatographic run time,"Transitions 456>166 for VER enantiomers, 441>166 for NOR enantiomers and 330>193 for the internal standard were monitored and the method had a total chromatographic run time of 12 min.",Simultaneous analysis of the enantiomers of verapamil and norverapamil in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17981422/),min,12,94549,DB00715,Paroxetine
,17981422,AUC ratio (-)/(+),"The concentration of (-)-(S)-VER was three folds higher than (+)-(R)-VER, with an AUC ratio (-)/(+) of 2.66.",Simultaneous analysis of the enantiomers of verapamil and norverapamil in rat plasma by liquid chromatography-tandem mass spectrometry. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17981422/),,2.66,94550,DB00715,Paroxetine
,17981422,Oral clearance,"Oral clearance values were 12.17 and 28.77 L/h/kg for (-)-(S)-VER and (+)-(R)-VER, respectively.",Simultaneous analysis of the enantiomers of verapamil and norverapamil in rat plasma by liquid chromatography-tandem mass spectrometry. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17981422/),[l] / [h·kg],12.17,94551,DB00715,Paroxetine
,17981422,Oral clearance,"Oral clearance values were 12.17 and 28.77 L/h/kg for (-)-(S)-VER and (+)-(R)-VER, respectively.",Simultaneous analysis of the enantiomers of verapamil and norverapamil in rat plasma by liquid chromatography-tandem mass spectrometry. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17981422/),[l] / [h·kg],28.77,94552,DB00715,Paroxetine
,15866490,flow-rate,"The HPLC separation of the analytes was performed on a MACHEREY-NAGEL C(18) (250 mmx4.6 mm, 5 microm, Germany) column, using water (formic acid 0.6 per thousand, ammonium acetate: 30 mmol/l)-acetonitrile (35:65, v/v) as mobile phase, with a flow-rate of 0.85 ml/min.","Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866490/),[ml] / [min],0.85,96981,DB00715,Paroxetine
above,15866490,extraction recoveries,The average extraction recoveries for all the four analytes were above 73.2%.,"Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866490/),%,73.2,96982,DB00715,Paroxetine
higher,15866490,recoveries,The methodology recoveries were higher than 95.0%.,"Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866490/),%,95.0,96983,DB00715,Paroxetine
,15866490,limits of detection (LODs),"The limits of detection (LODs) were 0.5, 0.3, 0.3 and 0.1 ng/ml for fluoxetine, citalopram, paroxetine and venlafaxine, respectively.","Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866490/),[ng] / [ml],0.5,96984,DB00715,Paroxetine
,15866490,limits of detection (LODs),"The limits of detection (LODs) were 0.5, 0.3, 0.3 and 0.1 ng/ml for fluoxetine, citalopram, paroxetine and venlafaxine, respectively.","Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866490/),[ng] / [ml],0.3,96985,DB00715,Paroxetine
,15866490,limits of detection (LODs),"The limits of detection (LODs) were 0.5, 0.3, 0.3 and 0.1 ng/ml for fluoxetine, citalopram, paroxetine and venlafaxine, respectively.","Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866490/),[ng] / [ml],0.1,96986,DB00715,Paroxetine
,9521568,absolute recovery,The absolute recovery averaged 74% for venlafaxine and 67% for oxydesmethylvenlafaxine.,"Simultaneous measurement of venlafaxine and its major metabolite, oxydesmethylvenlafaxine, in human plasma by high-performance liquid chromatography with coulometric detection and utilisation of solid-phase extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9521568/),%,74,102558,DB00715,Paroxetine
,9521568,absolute recovery,The absolute recovery averaged 74% for venlafaxine and 67% for oxydesmethylvenlafaxine.,"Simultaneous measurement of venlafaxine and its major metabolite, oxydesmethylvenlafaxine, in human plasma by high-performance liquid chromatography with coulometric detection and utilisation of solid-phase extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9521568/),%,67,102559,DB00715,Paroxetine
,9521568,sensitivity,The sensitivity was 0.5 ng for both the analytes.,"Simultaneous measurement of venlafaxine and its major metabolite, oxydesmethylvenlafaxine, in human plasma by high-performance liquid chromatography with coulometric detection and utilisation of solid-phase extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9521568/),ng,0.5,102560,DB00715,Paroxetine
,2530793,plasma protein binding,Its plasma protein binding at therapeutically relevant concentrations is about 95%.,A review of the metabolism and pharmacokinetics of paroxetine in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530793/),%,95,104680,DB00715,Paroxetine
,2530793,terminal half-life,"The terminal half-life is about one day, although there is a wide intersubject variability (e.g. with 30 mg, a range of 7-65 hours was observed in a group of 28 healthy young subjects).",A review of the metabolism and pharmacokinetics of paroxetine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530793/),d,one,104681,DB00715,Paroxetine
,30463329,relative bioavailability (F,"Crucial pharmacokinetic parameters including peak-reaching time (Tmax), peak concentration (Cmax) and the area under the blood level-time curve (AUC0-48) of PHH-EC-SLTs and PAXIL® CR had no significant difference (p > 0.05) and the relative bioavailability (F = 97.97%) of PHH-EC-SLTs demonstrated their similar pharmacokinetic profiles in vivo.",Development of Paroxetine Hydrochloride Single Layer Controlled-Release Tablets Based on 3² Factorial Design. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30463329/),%,97.97,107526,DB00715,Paroxetine
,9408807,maximum QTc,"On the final day of coadministration, the rate-corrected QT interval (QTc) was unaltered compared with terfenadine dosed alone; maximum QTc values (mean [SEM]) were 404 (4) and 405 (5) msec, respectively.",Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408807/),ms,404,108506,DB00715,Paroxetine
,9408807,maximum QTc,"On the final day of coadministration, the rate-corrected QT interval (QTc) was unaltered compared with terfenadine dosed alone; maximum QTc values (mean [SEM]) were 404 (4) and 405 (5) msec, respectively.",Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408807/),ms,405,108507,DB00715,Paroxetine
,9408807,steady-state area under the curve (AUC)tau,Terfenadine pharmacokinetics were also unchanged; geometric mean steady-state area under the curve (AUC)tau values were 30.0 ng.hr/mL during coadministration compared with 30.8 ng.hr/mL when dosed alone (p > 0.05).,Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408807/),[h·ng] / [ml],30.0,108508,DB00715,Paroxetine
,9408807,steady-state area under the curve (AUC)tau,Terfenadine pharmacokinetics were also unchanged; geometric mean steady-state area under the curve (AUC)tau values were 30.0 ng.hr/mL during coadministration compared with 30.8 ng.hr/mL when dosed alone (p > 0.05).,Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408807/),[h·ng] / [ml],30.8,108509,DB00715,Paroxetine
,9408807,Cmax,The corresponding Cmax values were 3.68 and 3.64 ng/mL (p > 0.05).,Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408807/),[ng] / [ml],3.68,108510,DB00715,Paroxetine
,9408807,Cmax,The corresponding Cmax values were 3.68 and 3.64 ng/mL (p > 0.05).,Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408807/),[ng] / [ml],3.64,108511,DB00715,Paroxetine
,8513845,clearances,"During paroxetine, the median clearances were 22 l.h-1 and 18 l.h-1 in EMs and PMs respectively.",Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513845/),[l] / [h],22,114647,DB00715,Paroxetine
,8513845,clearances,"During paroxetine, the median clearances were 22 l.h-1 and 18 l.h-1 in EMs and PMs respectively.",Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513845/),[l] / [h],18,114648,DB00715,Paroxetine
,8513845,clearance via,"Before paroxetine, the median of desipramine clearance via 2-hydroxylation was 40-times higher in EMs than in PMs (56 and 1.4 l.h-1 respectively), but during paroxetine, it was only 2-times higher (6 and 2.9 l.h-1 respectively).",Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513845/),[l] / [h],56,114649,DB00715,Paroxetine
,8513845,clearance via,"Before paroxetine, the median of desipramine clearance via 2-hydroxylation was 40-times higher in EMs than in PMs (56 and 1.4 l.h-1 respectively), but during paroxetine, it was only 2-times higher (6 and 2.9 l.h-1 respectively).",Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513845/),[l] / [h],1.4,114650,DB00715,Paroxetine
,8513845,clearance via,"Before paroxetine, the median of desipramine clearance via 2-hydroxylation was 40-times higher in EMs than in PMs (56 and 1.4 l.h-1 respectively), but during paroxetine, it was only 2-times higher (6 and 2.9 l.h-1 respectively).",Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513845/),[l] / [h],6,114651,DB00715,Paroxetine
,8513845,clearance via,"Before paroxetine, the median of desipramine clearance via 2-hydroxylation was 40-times higher in EMs than in PMs (56 and 1.4 l.h-1 respectively), but during paroxetine, it was only 2-times higher (6 and 2.9 l.h-1 respectively).",Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513845/),[l] / [h],2.9,114652,DB00715,Paroxetine
,26396498,Overall treatment response rate,"Overall treatment response rate was 72%, and the incidence of ADR was 30%.",Exposure-outcome analysis in depressed patients treated with paroxetine using population pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26396498/),%,72,116806,DB00715,Paroxetine
below,32346890,trough levels,A significant number of ultrarapid (UM) phenotype subjects possessed trough levels below 20 ng/ml (73-76%) compared to extensive metabolisers (EM) (51-53%).,Precision dosing-based optimisation of paroxetine during pregnancy for poor and ultrarapid CYP2D6 metabolisers: a virtual clinical trial pharmacokinetics study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32346890/),[ng] / [ml],20,121416,DB00715,Paroxetine
,9068931,half-life (t1/2),Most SSRIs have a half-life (t1/2) of approximately 1 day.,Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068931/),d,1,129521,DB00715,Paroxetine
,9068931,t1/2,"Fluoxetine, however, has a longer t1/2 of 2 to 4 days, and its active metabolite, norfluoxetine, has an extended t1/2 of 7 to 15 days.",Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068931/),d,2 to 4,129522,DB00715,Paroxetine
,9068931,t1/2,"Fluoxetine, however, has a longer t1/2 of 2 to 4 days, and its active metabolite, norfluoxetine, has an extended t1/2 of 7 to 15 days.",Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068931/),d,7 to 15,129523,DB00715,Paroxetine
,9679303,Recoveries,"Recoveries measured at three concentrations range from 81 to 118% for the tertiary amines (citalopram and the internal standard methylmaprotiline), 73 to 95% for the secondary amines (desmethylcitalopram, paroxetine and sertraline), and 39 to 66% for the primary amines (didesmethylcitalopram and desmethylsertraline).","Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9679303/),%,81 to 118,129741,DB00715,Paroxetine
,9679303,Recoveries,"Recoveries measured at three concentrations range from 81 to 118% for the tertiary amines (citalopram and the internal standard methylmaprotiline), 73 to 95% for the secondary amines (desmethylcitalopram, paroxetine and sertraline), and 39 to 66% for the primary amines (didesmethylcitalopram and desmethylsertraline).","Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9679303/),%,73 to 95,129742,DB00715,Paroxetine
,9679303,Recoveries,"Recoveries measured at three concentrations range from 81 to 118% for the tertiary amines (citalopram and the internal standard methylmaprotiline), 73 to 95% for the secondary amines (desmethylcitalopram, paroxetine and sertraline), and 39 to 66% for the primary amines (didesmethylcitalopram and desmethylsertraline).","Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9679303/),%,39 to 66,129743,DB00715,Paroxetine
,26754303,tmax,The absorption of controlled-release paroxetine was delayed with a median tmax of 8 - 10 hours and the mean t1/2 was 12 - 14 hours across all doses.,Pharmacokinetics and safety of paroxetine controlled-release tablet in healthy Chinese subjects: a single-dose three-period crossover study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26754303/),h,8 - 10,133095,DB00715,Paroxetine
,26754303,t1/2,The absorption of controlled-release paroxetine was delayed with a median tmax of 8 - 10 hours and the mean t1/2 was 12 - 14 hours across all doses.,Pharmacokinetics and safety of paroxetine controlled-release tablet in healthy Chinese subjects: a single-dose three-period crossover study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26754303/),h,12 - 14,133096,DB00715,Paroxetine
,26754303,Cmax,"Over the dose range of 12.5 - 37.5 mg, the mean Cmax increased from 2.62 to 15.13 ng/mL and AUC0-∞ increased from 63.56 to 404.91 h×ng/mL.",Pharmacokinetics and safety of paroxetine controlled-release tablet in healthy Chinese subjects: a single-dose three-period crossover study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26754303/),[ng] / [ml],2,133097,DB00715,Paroxetine
,26754303,AUC0-∞,"Over the dose range of 12.5 - 37.5 mg, the mean Cmax increased from 2.62 to 15.13 ng/mL and AUC0-∞ increased from 63.56 to 404.91 h×ng/mL.",Pharmacokinetics and safety of paroxetine controlled-release tablet in healthy Chinese subjects: a single-dose three-period crossover study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26754303/),[h·ng] / [ml],63,133098,DB00715,Paroxetine
,26754303,AUC0-∞,"Over the dose range of 12.5 - 37.5 mg, the mean Cmax increased from 2.62 to 15.13 ng/mL and AUC0-∞ increased from 63.56 to 404.91 h×ng/mL.",Pharmacokinetics and safety of paroxetine controlled-release tablet in healthy Chinese subjects: a single-dose three-period crossover study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26754303/),[h·ng] / [ml],404,133099,DB00715,Paroxetine
,21618564,total run time,"The total run time was 1.5 min and the elution of ESZ and IS occurred at 0.90 min; this was achieved with a mobile phase consisting of 0.1% formic acid-methanol (15:85, v/v) at a flow rate of 0.50 mL/min on a Discover C(18) (50 × 4.6 mm, 5 µm) column.",A rapid LC-MS/MS method for quantitation of eszopiclone in human plasma: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21618564/),min,1.5,133948,DB00715,Paroxetine
,21618564,flow rate,"The total run time was 1.5 min and the elution of ESZ and IS occurred at 0.90 min; this was achieved with a mobile phase consisting of 0.1% formic acid-methanol (15:85, v/v) at a flow rate of 0.50 mL/min on a Discover C(18) (50 × 4.6 mm, 5 µm) column.",A rapid LC-MS/MS method for quantitation of eszopiclone in human plasma: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21618564/),[ml] / [min],0.50,133949,DB00715,Paroxetine
,10546982,production rate constant,"In the hippocampus, the production rate constant was 2.36 fmol mg protein (-1)h(-1); the degradation rate constant was 0.0077 h(-1); and the half-life of the SERT recovery was 3.4 days.",Serotonin transporter production and degradation rates: studies with RTI-76. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546982/),[fmol·mg] / [(-1)h],2.36,134522,DB00715,Paroxetine
,10546982,degradation rate constant,"In the hippocampus, the production rate constant was 2.36 fmol mg protein (-1)h(-1); the degradation rate constant was 0.0077 h(-1); and the half-life of the SERT recovery was 3.4 days.",Serotonin transporter production and degradation rates: studies with RTI-76. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546982/),1/[h],0.0077,134523,DB00715,Paroxetine
,10546982,half-life of,"In the hippocampus, the production rate constant was 2.36 fmol mg protein (-1)h(-1); the degradation rate constant was 0.0077 h(-1); and the half-life of the SERT recovery was 3.4 days.",Serotonin transporter production and degradation rates: studies with RTI-76. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546982/),d,3.4,134524,DB00715,Paroxetine
,20705902,AUC ratio,"R/S AUC ratio increased significantly, from approximately 2.3 to 3.0.",The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20705902/),,2.3,137471,DB00715,Paroxetine
,20705902,AUC ratio,"R/S AUC ratio increased significantly, from approximately 2.3 to 3.0.",The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20705902/),,3.0,137472,DB00715,Paroxetine
,22435778,T(max),Oral administration of paroxetine HCl dissolved in water resulted in a relatively slow absorption (T(max)=5.9±2.6 h) and a low bioavailability (31±15%).,"Pharmacokinetics of paroxetine, a selective serotonin reuptake inhibitor, in Grey parrots (Psittacus erithacus erithacus): influence of pharmaceutical formulation and length of dosing. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22435778/),h,5.9,140636,DB00715,Paroxetine
,22435778,bioavailability,Oral administration of paroxetine HCl dissolved in water resulted in a relatively slow absorption (T(max)=5.9±2.6 h) and a low bioavailability (31±15%).,"Pharmacokinetics of paroxetine, a selective serotonin reuptake inhibitor, in Grey parrots (Psittacus erithacus erithacus): influence of pharmaceutical formulation and length of dosing. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22435778/),%,31,140637,DB00715,Paroxetine
,23795577,Tmax,"On day 1, median Tmax was ~6 hours, and mean t1/2 was 17.30 hours.",Pharmacokinetic properties of once-daily oral low-dose mesylate salt of paroxetine (LDMP 7.5 mg) following single and multiple doses in healthy postmenopausal women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23795577/),h,6,147371,DB00715,Paroxetine
,23795577,t1/2,"On day 1, median Tmax was ~6 hours, and mean t1/2 was 17.30 hours.",Pharmacokinetic properties of once-daily oral low-dose mesylate salt of paroxetine (LDMP 7.5 mg) following single and multiple doses in healthy postmenopausal women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23795577/),h,17.30,147372,DB00715,Paroxetine
,23795577,accumulation index (AUCday 19/AUCday 1) at,"Mean Cmax on day 14 of multiple dosing was ~5-fold greater than that attained on day 1, and the accumulation index (AUCday 19/AUCday 1) at steady state was 9.71.",Pharmacokinetic properties of once-daily oral low-dose mesylate salt of paroxetine (LDMP 7.5 mg) following single and multiple doses in healthy postmenopausal women. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23795577/),,9.71,147373,DB00715,Paroxetine
,20063149,total run time,Derivatives were then separated on a gas chromatograph coupled with a triple-quadrupole mass spectrometer operating in negative selected reaction monitoring mode for a total run time of 5 min.,"Use of the dried blood spot sampling process coupled with fast gas chromatography and negative-ion chemical ionization tandem mass spectrometry: application to fluoxetine, norfluoxetine, reboxetine, and paroxetine analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20063149/),min,5,147690,DB00715,Paroxetine
,20063149,limit of detection,"Despite the small sampling volume, the limit of detection was estimated at 20 pg mL(-1) for all the analytes.","Use of the dried blood spot sampling process coupled with fast gas chromatography and negative-ion chemical ionization tandem mass spectrometry: application to fluoxetine, norfluoxetine, reboxetine, and paroxetine analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20063149/),[pg] / [ml],20,147691,DB00715,Paroxetine
,8106653,severity of illness,"Similarly, the CGI severity of illness score declined from 4.6 at baseline to 2.8 at week 6 and to 1.7 at the end of 1 year.",Long-term treatment of major depressive disorder with paroxetine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106653/),,4.6,149345,DB00715,Paroxetine
,8106653,severity of illness,"Similarly, the CGI severity of illness score declined from 4.6 at baseline to 2.8 at week 6 and to 1.7 at the end of 1 year.",Long-term treatment of major depressive disorder with paroxetine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106653/),,2.8,149346,DB00715,Paroxetine
,24868171,Km,"The mean values of Km and Vmax were 50.5±68.4 ng/mL and 50.6±18.8 mg/day, respectively.",Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24868171/),[ng] / [ml],50.5,149693,DB00715,Paroxetine
,24868171,Vmax,"The mean values of Km and Vmax were 50.5±68.4 ng/mL and 50.6±18.8 mg/day, respectively.",Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24868171/),[mg] / [d],50.6,149694,DB00715,Paroxetine
,24868171,Km,"Both the Km and Vmax values were significantly smaller in CYP2D6*10 allele carriers than in the noncarriers (24.2±18.3 ng/mL versus 122.5±106.3 ng/mL, P=0.008; 44.2±16.1 mg/day versus 68.3±15.0 mg/day, P=0.022, respectively).",Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24868171/),[ng] / [ml],24.2,149695,DB00715,Paroxetine
,24868171,Km,"Both the Km and Vmax values were significantly smaller in CYP2D6*10 allele carriers than in the noncarriers (24.2±18.3 ng/mL versus 122.5±106.3 ng/mL, P=0.008; 44.2±16.1 mg/day versus 68.3±15.0 mg/day, P=0.022, respectively).",Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24868171/),[ng] / [ml],122.5,149696,DB00715,Paroxetine
,24868171,Vmax,"Both the Km and Vmax values were significantly smaller in CYP2D6*10 allele carriers than in the noncarriers (24.2±18.3 ng/mL versus 122.5±106.3 ng/mL, P=0.008; 44.2±16.1 mg/day versus 68.3±15.0 mg/day, P=0.022, respectively).",Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24868171/),[mg] / [d],44.2,149697,DB00715,Paroxetine
,24868171,Vmax,"Both the Km and Vmax values were significantly smaller in CYP2D6*10 allele carriers than in the noncarriers (24.2±18.3 ng/mL versus 122.5±106.3 ng/mL, P=0.008; 44.2±16.1 mg/day versus 68.3±15.0 mg/day, P=0.022, respectively).",Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24868171/),[mg] / [d],68.3,149698,DB00715,Paroxetine
,1531816,elimination half-life,"With the exception of fluoxetine, which has an elimination half-life of 2 to 3 days, the other drugs have half-lives of about 1 day.",Pharmacokinetics of the selective serotonin reuptake inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531816/),d,2 to 3,152373,DB00715,Paroxetine
,1531816,half-lives,"With the exception of fluoxetine, which has an elimination half-life of 2 to 3 days, the other drugs have half-lives of about 1 day.",Pharmacokinetics of the selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531816/),d,1,152374,DB00715,Paroxetine
,17099560,bioavailability,Its mean bioavailability is around 75%.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),%,75,153478,DB00715,Paroxetine
,17099560,volume of distribution,Its volume of distribution is of around 4 L/kg.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),[l] / [kg],4,153479,DB00715,Paroxetine
,17099560,half-life elimination,The value of half-life elimination is of around 22 hours.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),h,22,153480,DB00715,Paroxetine
,17099560,bioavibility,"Thus, bioavibility ranges from 36 to 100%.",[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),%,36 to 100,153481,DB00715,Paroxetine
,17099560,plasmatic target,The methadone plasmatic target value of 400 microg/ml can be recommended for therapeutic drug monitoring.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),[μg] / [ml],400,153482,DB00715,Paroxetine
,9472836,elimination half-life,Estimation of the mean elimination half-life of clozapine 2 weeks after start of fluvoxamine comedication revealed an increase from 17 hours to about 50 hours whereas there was no change under paroxetine coadministration.,Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9472836/),h,17,154901,DB00715,Paroxetine
,9472836,elimination half-life,Estimation of the mean elimination half-life of clozapine 2 weeks after start of fluvoxamine comedication revealed an increase from 17 hours to about 50 hours whereas there was no change under paroxetine coadministration.,Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9472836/),h,50,154902,DB00715,Paroxetine
,433623,t1-z2,"The pharmacokinetic studies revealed a dose dependent systemic availability, a rather slow elimination (t1-z2 = approximately 16 hrs), a good fit to one compartment open model, and an almost complete metabolism of the substance.","Paroxetine: pharmacokinetics, tolerance and depletion of blood 5-HT in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/433623/),h,16,155421,DB00715,Paroxetine
,20156150,elimination half-life,The elimination half-life of galantamine is about 7-8 hours.,"A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy subjects and patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20156150/),h,7-8,155466,DB00715,Paroxetine
,20156150,protein binding,Galantamine has low protein binding (28.3-33.8%) and has an apparent steady-state volume of distribution (V(ss)) of 193 L.,"A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy subjects and patients. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20156150/),%,28.3-33.8,155467,DB00715,Paroxetine
,20156150,apparent steady-state volume of distribution (V(ss)),Galantamine has low protein binding (28.3-33.8%) and has an apparent steady-state volume of distribution (V(ss)) of 193 L.,"A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy subjects and patients. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20156150/),l,193,155468,DB00715,Paroxetine
,21142269,elimination half-life,"The combination of paroxetine and itraconazole prolonged the mean elimination half-life of oxycodone from 3.8 to 6.6 hours (p < 0.001), and increased the exposure to oxycodone 2-fold (p < 0.001).","Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21142269/),h,3.8,164029,DB00715,Paroxetine
,21142269,elimination half-life,"The combination of paroxetine and itraconazole prolonged the mean elimination half-life of oxycodone from 3.8 to 6.6 hours (p < 0.001), and increased the exposure to oxycodone 2-fold (p < 0.001).","Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21142269/),h,6,164030,DB00715,Paroxetine
,18641553,concentration,"Paroxetine concentration significantly differed between female and male patients (median, 28 versus 16 ng/mL; P = 0.001).",CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641553/),[ng] / [ml],28,176575,DB00715,Paroxetine
,18641553,concentration,"Paroxetine concentration significantly differed between female and male patients (median, 28 versus 16 ng/mL; P = 0.001).",CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641553/),[ng] / [ml],16,176576,DB00715,Paroxetine
,21496064,terminal half-life (t(1/2) ),"Co-administration of multiple oral doses of 20 mg paroxetine once daily with a single oral dose of the 0.4 mg tamsulosin HCl capsule increased the adjusted geometric mean (gMean) values of C(max) and AUC(0,∞) of tamsulosin by factors of 1.34 (90% CI 1.21, 1.49) and 1.64 (90% CI 1.44, 1.85), respectively, and increased the terminal half-life (t(1/2) ) of tamsulosin HCl from 11.4 h to 15.3 h.","Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21496064/),h,11.4,177627,DB00715,Paroxetine
,21496064,terminal half-life (t(1/2) ),"Co-administration of multiple oral doses of 20 mg paroxetine once daily with a single oral dose of the 0.4 mg tamsulosin HCl capsule increased the adjusted geometric mean (gMean) values of C(max) and AUC(0,∞) of tamsulosin by factors of 1.34 (90% CI 1.21, 1.49) and 1.64 (90% CI 1.44, 1.85), respectively, and increased the terminal half-life (t(1/2) ) of tamsulosin HCl from 11.4 h to 15.3 h.","Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21496064/),h,15.3,177628,DB00715,Paroxetine
,21496064,terminal half-life,The terminal half-life was slightly increased from 10.5 h to 11.8 h.,"Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21496064/),h,10.5,177629,DB00715,Paroxetine
,21496064,terminal half-life,The terminal half-life was slightly increased from 10.5 h to 11.8 h.,"Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21496064/),h,11.8,177630,DB00715,Paroxetine
,23355638,steady-state plasma concentration (Css) ratio,The predicted mean PAR steady-state plasma concentration (Css) ratio (PP:T3) was 7.1 versus the observed value 3.7.,A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355638/),,7.1,179595,DB00715,Paroxetine
,23355638,steady-state plasma concentration (Css) ratio,The predicted mean PAR steady-state plasma concentration (Css) ratio (PP:T3) was 7.1 versus the observed value 3.7.,A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355638/),,3.7,179596,DB00715,Paroxetine
,23355638,AUC ratio,Predicted mean CLO AUC ratio (PP:T3) was 2.2 versus the observed value 1.7.,A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355638/),,2.2,179597,DB00715,Paroxetine
,23355638,AUC ratio,Predicted mean CLO AUC ratio (PP:T3) was 2.2 versus the observed value 1.7.,A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355638/),,1.7,179598,DB00715,Paroxetine
,17304149,peak plasma concentration (Cmax),"Compared with placebo, itraconazole treatment significantly increased the peak plasma concentration (Cmax) of paroxetine by 1.3 fold (6.7 +/- 2.5 versus 9.0 +/- 3.3 ng/mL, P < 0.05) and the area under the plasma concentration-time curve from zero to 48 hours [AUC (0-48)] of paroxetine by 1.5 fold (137 +/- 73 versus 199 +/- 91 ng*h/mL, P < 0.01).",Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17304149/),[ng] / [ml],6.7,180180,DB00715,Paroxetine
,17304149,peak plasma concentration (Cmax),"Compared with placebo, itraconazole treatment significantly increased the peak plasma concentration (Cmax) of paroxetine by 1.3 fold (6.7 +/- 2.5 versus 9.0 +/- 3.3 ng/mL, P < 0.05) and the area under the plasma concentration-time curve from zero to 48 hours [AUC (0-48)] of paroxetine by 1.5 fold (137 +/- 73 versus 199 +/- 91 ng*h/mL, P < 0.01).",Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17304149/),[ng] / [ml],9.0,180181,DB00715,Paroxetine
,17304149,area under the plasma concentration-time curve from zero to 48 hours [AUC (0-48)],"Compared with placebo, itraconazole treatment significantly increased the peak plasma concentration (Cmax) of paroxetine by 1.3 fold (6.7 +/- 2.5 versus 9.0 +/- 3.3 ng/mL, P < 0.05) and the area under the plasma concentration-time curve from zero to 48 hours [AUC (0-48)] of paroxetine by 1.5 fold (137 +/- 73 versus 199 +/- 91 ng*h/mL, P < 0.01).",Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17304149/),[h·ng] / [ml],137,180182,DB00715,Paroxetine
,17304149,area under the plasma concentration-time curve from zero to 48 hours [AUC (0-48)],"Compared with placebo, itraconazole treatment significantly increased the peak plasma concentration (Cmax) of paroxetine by 1.3 fold (6.7 +/- 2.5 versus 9.0 +/- 3.3 ng/mL, P < 0.05) and the area under the plasma concentration-time curve from zero to 48 hours [AUC (0-48)] of paroxetine by 1.5 fold (137 +/- 73 versus 199 +/- 91 ng*h/mL, P < 0.01).",Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17304149/),[h·ng] / [ml],199,180183,DB00715,Paroxetine
,17304149,elimination half-life,"Although elimination half-life differed significantly (16.1 +/- 3.4 versus 18.8 +/- 5.9 hours, P < 0.05), the alteration was small (1.1 fold).",Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17304149/),h,16.1,180184,DB00715,Paroxetine
,17304149,elimination half-life,"Although elimination half-life differed significantly (16.1 +/- 3.4 versus 18.8 +/- 5.9 hours, P < 0.05), the alteration was small (1.1 fold).",Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17304149/),h,18.8,180185,DB00715,Paroxetine
,12820211,recoveries,"Mean recoveries of 77% for paroxetine and 76% for HM paroxetine were found, with precision always better than 15%.",Quantitative determination of paroxetine and its 4-hydroxy-3-methoxy metabolite in plasma by high-performance liquid chromatography/electrospray ion trap mass spectrometry: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820211/),%,77,182634,DB00715,Paroxetine
,12820211,recoveries,"Mean recoveries of 77% for paroxetine and 76% for HM paroxetine were found, with precision always better than 15%.",Quantitative determination of paroxetine and its 4-hydroxy-3-methoxy metabolite in plasma by high-performance liquid chromatography/electrospray ion trap mass spectrometry: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820211/),%,76,182635,DB00715,Paroxetine
,12820211,limits of detection,"The limits of detection and quantification were 0.20 and 0.70 microg/L for paroxetine, and 0.70 and 2.20 microg/L for its metabolite.",Quantitative determination of paroxetine and its 4-hydroxy-3-methoxy metabolite in plasma by high-performance liquid chromatography/electrospray ion trap mass spectrometry: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820211/),[μg] / [l],0.20,182636,DB00715,Paroxetine
,12820211,limits of detection,"The limits of detection and quantification were 0.20 and 0.70 microg/L for paroxetine, and 0.70 and 2.20 microg/L for its metabolite.",Quantitative determination of paroxetine and its 4-hydroxy-3-methoxy metabolite in plasma by high-performance liquid chromatography/electrospray ion trap mass spectrometry: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820211/),[μg] / [l],0.70,182637,DB00715,Paroxetine
,12820211,limits of detection,"The limits of detection and quantification were 0.20 and 0.70 microg/L for paroxetine, and 0.70 and 2.20 microg/L for its metabolite.",Quantitative determination of paroxetine and its 4-hydroxy-3-methoxy metabolite in plasma by high-performance liquid chromatography/electrospray ion trap mass spectrometry: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820211/),[μg] / [l],2.20,182638,DB00715,Paroxetine
,12820211,peak plasma concentration,"After the 20-mg dose, the mean peak plasma concentration was 8.60 microg/L for paroxetine and 92.40 microg/L for HM paroxetine showing a tenfold ratio between the metabolite and the parent drug along the entire time-concentration curve.",Quantitative determination of paroxetine and its 4-hydroxy-3-methoxy metabolite in plasma by high-performance liquid chromatography/electrospray ion trap mass spectrometry: application to pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820211/),[μg] / [l],8.60,182639,DB00715,Paroxetine
,12820211,peak plasma concentration,"After the 20-mg dose, the mean peak plasma concentration was 8.60 microg/L for paroxetine and 92.40 microg/L for HM paroxetine showing a tenfold ratio between the metabolite and the parent drug along the entire time-concentration curve.",Quantitative determination of paroxetine and its 4-hydroxy-3-methoxy metabolite in plasma by high-performance liquid chromatography/electrospray ion trap mass spectrometry: application to pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820211/),[μg] / [l],92.40,182640,DB00715,Paroxetine
,25864807,flow rate,"Chromatographic separation was achieved on a cyanopropyl bonded-phase column with a mobile phase composed of 50 m m potassium dihydrogen phosphate buffer (pH 4.5) and acetonitrile (75:25, v/v), pumped at the flow rate of 1 mL/min.",Sensitive and precise HPLC method with back-extraction clean-up step for the determination of sildenafil in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25864807/),[ml] / [min],1,192029,DB00715,Paroxetine
,25864807,limit of detection,The limit of detection was 5 ng/mL.,Sensitive and precise HPLC method with back-extraction clean-up step for the determination of sildenafil in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25864807/),[ng] / [ml],5,192030,DB00715,Paroxetine
,25864807,recovery,The recovery of sildenafil was 85.22 ± 4.54%.,Sensitive and precise HPLC method with back-extraction clean-up step for the determination of sildenafil in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25864807/),%,85.22,192031,DB00715,Paroxetine
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,6.1,192732,DB00715,Paroxetine
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,7.1,192733,DB00715,Paroxetine
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,26.5,192734,DB00715,Paroxetine
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,16.7,192735,DB00715,Paroxetine
,34287102,metabolic ratio,"M1 metabolic ratio (0.12) was 2-fold reduced, M2 metabolic ratio (197) 1000-fold increased and M5 metabolic ratio (0.12) normal.",Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),,0.12,192736,DB00715,Paroxetine
,34287102,metabolic ratio,"M1 metabolic ratio (0.12) was 2-fold reduced, M2 metabolic ratio (197) 1000-fold increased and M5 metabolic ratio (0.12) normal.",Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),,197,192737,DB00715,Paroxetine
,9241008,maximum concentration in plasma (Cmax),"After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).",Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241008/),[ng] / [ml],37.8 to 173,192832,DB00715,Paroxetine
,9241008,maximum concentration in plasma (Cmax),"After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).",Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241008/),[ng] / [ml],36.1 to 51.9,192833,DB00715,Paroxetine
,9241008,area under the concentration-time curve (AUC[24]),"After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).",Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241008/),[h·ng] / [ml],"634 to 3,305",192834,DB00715,Paroxetine
,9241008,area under the concentration-time curve (AUC[24]),"After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).",Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241008/),[h·ng] / [ml],611 to 838,192835,DB00715,Paroxetine
,9241008,trough value (C0),"After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).",Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241008/),[ng] / [ml],18.5 to 113,192836,DB00715,Paroxetine
,9241008,trough value (C0),"After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).",Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241008/),[ng] / [ml],18.3 to 21.8,192837,DB00715,Paroxetine
,10885584,absolute bioavailability,"The absolute bioavailability is approximately 50%, mainly because of gut wall and hepatic first-pass metabolism.",Clinical pharmacokinetics of mirtazapine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),%,50,193151,DB00715,Paroxetine
,10885584,elimination half-life,"The elimination half-life of mirtazapine ranges from 20 to 40 hours, which is in agreement with the time to reach steady state (4 to 6 days).",Clinical pharmacokinetics of mirtazapine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),h,20 to 40,193152,DB00715,Paroxetine
,10885584,time to reach steady state,"The elimination half-life of mirtazapine ranges from 20 to 40 hours, which is in agreement with the time to reach steady state (4 to 6 days).",Clinical pharmacokinetics of mirtazapine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),d,4 to 6,193153,DB00715,Paroxetine
,10885584,Total body clearance,Total body clearance as determined from intravenous administration to young males amounts to 31 L/h.,Clinical pharmacokinetics of mirtazapine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),[l] / [h],31,193154,DB00715,Paroxetine
,10885584,half-life,"The pharmacokinetics of mirtazapine appears to be enantioselective, resulting in higher plasma concentrations and longer half-life of the (R)-(-)-enantiomer (18.0 +/-2.5h) compared with that of the (S)-(+)-enantiomer (9.9+/-3. lh).",Clinical pharmacokinetics of mirtazapine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),h,18.0,193155,DB00715,Paroxetine
,10885584,half-life,"The pharmacokinetics of mirtazapine appears to be enantioselective, resulting in higher plasma concentrations and longer half-life of the (R)-(-)-enantiomer (18.0 +/-2.5h) compared with that of the (S)-(+)-enantiomer (9.9+/-3. lh).",Clinical pharmacokinetics of mirtazapine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),h,9.9,193156,DB00715,Paroxetine
up to,22283559,AU,"In group 1 (n = 14), addition of DMQ to paroxetine resulted in a 30% increase in mean plasma exposure of paroxetine (AUC up to 24 hours).",Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283559/),h,24,196520,DB00715,Paroxetine
,8384945,Absolute bioavailability,"Absolute bioavailability of citalopram is almost 100%, whereas it is likely that the other compounds undergo (substantial) first-pass metabolism.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,100,201450,DB00715,Paroxetine
,8384945,Apparent oral clearance,"Apparent oral clearance values after single doses range from 26 L/h (citalopram) to 167 L/h (paroxetine), while after multiple doses oral clearance is markedly reduced, particularly for fluoxetine and paroxetine.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),[l] / [h],26,201451,DB00715,Paroxetine
,8384945,Apparent oral clearance,"Apparent oral clearance values after single doses range from 26 L/h (citalopram) to 167 L/h (paroxetine), while after multiple doses oral clearance is markedly reduced, particularly for fluoxetine and paroxetine.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),[l] / [h],167,201452,DB00715,Paroxetine
> or =,8384945,Plasma protein binding,"Plasma protein binding of fluoxetine, paroxetine and sertraline is > or = 95%; values for fluvoxamine (77%) and citalopram (50%) are much lower.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,95,201453,DB00715,Paroxetine
,8384945,Plasma protein binding,"Plasma protein binding of fluoxetine, paroxetine and sertraline is > or = 95%; values for fluvoxamine (77%) and citalopram (50%) are much lower.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,77,201454,DB00715,Paroxetine
,8384945,Plasma protein binding,"Plasma protein binding of fluoxetine, paroxetine and sertraline is > or = 95%; values for fluvoxamine (77%) and citalopram (50%) are much lower.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,50,201455,DB00715,Paroxetine
,8384945,half-lives,"The half-lives of fluvoxamine, paroxetine, sertraline and citalopram are approximately 1 day.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,1,201456,DB00715,Paroxetine
,8384945,half-life,"The half-life of fluoxetine is approximately 2 days (6 days after multiple doses), and that of the active metabolite norfluoxetine is 7 to 15 days.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,2,201457,DB00715,Paroxetine
,8384945,half-life,"The half-life of fluoxetine is approximately 2 days (6 days after multiple doses), and that of the active metabolite norfluoxetine is 7 to 15 days.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,6,201458,DB00715,Paroxetine
,8384945,half-life,"The half-life of fluoxetine is approximately 2 days (6 days after multiple doses), and that of the active metabolite norfluoxetine is 7 to 15 days.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,7 to 15,201459,DB00715,Paroxetine
,8846617,oral bioavailability,"Despite complete absorption, oral bioavailability in man is approximately 50% on account of first-pass hepatic metabolism.",Overview of the pharmacokinetics of fluvoxamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846617/),%,50,204181,DB00715,Paroxetine
,8846617,terminal elimination half-life,Fluvoxamine shows a biphasic pattern of elimination with a mean terminal elimination half-life of 12 to 15 hours after a single oral dose; this is prolonged by 30 to 50% at steady-state.,Overview of the pharmacokinetics of fluvoxamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846617/),h,12 to 15,204182,DB00715,Paroxetine
,8846617,Plasma protein binding,Plasma protein binding of fluvoxamine (77%) is low compared with that of other SSRIs.,Overview of the pharmacokinetics of fluvoxamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846617/),%,77,204183,DB00715,Paroxetine
,7959522,bioavailability,It undergoes a partially saturated first pass metabolism which reduces the bioavailability at therapeutic doses to about 30-60%.,[Paroxetine: pharmacokinetics and pharmacodynamics]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7959522/),%,30-60,208892,DB00715,Paroxetine
,16669849,Vm,"The Vm estimates in each of the CYP2D6 phenotypic groups were: 125 microg h-1 in poor metabolizer (n=1), 182 microg h-1 in intermediate metabolizers (n=28), 454 microg h-1 in extensive metabolizers (n=36) and 3670 microg h-1 in ultra-rapid metabolizers (n=5).",Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669849/),[μg] / [h],125,209123,DB00715,Paroxetine
,16669849,Vm,"The Vm estimates in each of the CYP2D6 phenotypic groups were: 125 microg h-1 in poor metabolizer (n=1), 182 microg h-1 in intermediate metabolizers (n=28), 454 microg h-1 in extensive metabolizers (n=36) and 3670 microg h-1 in ultra-rapid metabolizers (n=5).",Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669849/),[μg] / [h],182,209124,DB00715,Paroxetine
,16669849,Vm,"The Vm estimates in each of the CYP2D6 phenotypic groups were: 125 microg h-1 in poor metabolizer (n=1), 182 microg h-1 in intermediate metabolizers (n=28), 454 microg h-1 in extensive metabolizers (n=36) and 3670 microg h-1 in ultra-rapid metabolizers (n=5).",Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669849/),[μg] / [h],454,209125,DB00715,Paroxetine
,16669849,Vm,"The Vm estimates in each of the CYP2D6 phenotypic groups were: 125 microg h-1 in poor metabolizer (n=1), 182 microg h-1 in intermediate metabolizers (n=28), 454 microg h-1 in extensive metabolizers (n=36) and 3670 microg h-1 in ultra-rapid metabolizers (n=5).",Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669849/),[μg] / [h],3670,209126,DB00715,Paroxetine
,25078020,concentration,Median mirtazapine concentration was 43.6 μg/L (164.37 nmol) at a daily dosage range of 7.5-60 mg.,Therapeutic drug monitoring of mirtazapine in a routine outpatient setting in Asian psychiatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25078020/),[μg] / [l],43.6,215752,DB00715,Paroxetine
,25078020,concentration-to-dose (C/D) ratio,"Mean concentration-to-dose (C/D) ratio was 1.48 μg/L/mg/day (5.58 nmol/mg/day), which was higher than that in a previous study in Caucasian subjects.",Therapeutic drug monitoring of mirtazapine in a routine outpatient setting in Asian psychiatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25078020/),[μg] / [d·l·mg],1.48,215753,DB00715,Paroxetine
,25078020,concentration-to-dose (C/D) ratio,"Mean concentration-to-dose (C/D) ratio was 1.48 μg/L/mg/day (5.58 nmol/mg/day), which was higher than that in a previous study in Caucasian subjects.",Therapeutic drug monitoring of mirtazapine in a routine outpatient setting in Asian psychiatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25078020/),[nM] / [d·mg],5.58,215754,DB00715,Paroxetine
,14872546,run time,"The chromatographic run time was 2.0 min per injection, with retention times of 1.1 and 1.2 min for paroxetine and IS, respectively.",Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the analysis of paroxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14872546/),[min] / [injection],2.0,217809,DB00715,Paroxetine
,14872546,retention times,"The chromatographic run time was 2.0 min per injection, with retention times of 1.1 and 1.2 min for paroxetine and IS, respectively.",Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the analysis of paroxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14872546/),min,1.1,217810,DB00715,Paroxetine
,14872546,retention times,"The chromatographic run time was 2.0 min per injection, with retention times of 1.1 and 1.2 min for paroxetine and IS, respectively.",Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the analysis of paroxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14872546/),min,1.2,217811,DB00715,Paroxetine
,28911626,relative recoveries,"The method was validated over a concentration range of 0.1-100 ng/mL for all the three analytes, with relative recoveries ranging from 69% to 82%.","High-throughput liquid chromatography tandem mass spectrometry method for simultaneous determination of fampridine, paroxetine, and quinidine in rat plasma: Application to in vivo perfusion study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28911626/),%,69,217913,DB00715,Paroxetine
,28911626,relative recoveries,"The method was validated over a concentration range of 0.1-100 ng/mL for all the three analytes, with relative recoveries ranging from 69% to 82%.","High-throughput liquid chromatography tandem mass spectrometry method for simultaneous determination of fampridine, paroxetine, and quinidine in rat plasma: Application to in vivo perfusion study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28911626/),%,82,217914,DB00715,Paroxetine
,25651476,Tmax,"Compared with placebo-pretreated subjects, paroxetine-pretreated subjects had rapid (Tmax = 1.5 hours) and substantial absorption of ibogaine, with detectable levels out to 72 hours, and an elimination half-life of 10.2 hours.",Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25651476/),h,1.5,224676,DB00715,Paroxetine
,25651476,elimination half-life,"Compared with placebo-pretreated subjects, paroxetine-pretreated subjects had rapid (Tmax = 1.5 hours) and substantial absorption of ibogaine, with detectable levels out to 72 hours, and an elimination half-life of 10.2 hours.",Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25651476/),h,10.2,224677,DB00715,Paroxetine
,25651476,Tmax,"In this group, ibogaine was also rapidly converted to noribogaine with a median Tmax of 3 hours.",Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25651476/),h,3,224678,DB00715,Paroxetine
,28962699,plasma concentration ratio,"The model predicted a maternal-fetal plasma concentration ratio of 0.376 after repeated maternal administration of fluvoxamine, similar to the ratio for paroxetine.",Quantitative prediction of fetal plasma concentration of fluvoxamine during dosage-tapering to the mother. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28962699/),,0.376,227409,DB00715,Paroxetine
,28962699,half-life,"However, if the mother ceased taking drug, the model predicted a half-life of fluvoxamine in fetal plasma of 35 h, which is longer than that of paroxetine (10 h).",Quantitative prediction of fetal plasma concentration of fluvoxamine during dosage-tapering to the mother. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28962699/),h,35,227410,DB00715,Paroxetine
,28962699,half-life,"However, if the mother ceased taking drug, the model predicted a half-life of fluvoxamine in fetal plasma of 35 h, which is longer than that of paroxetine (10 h).",Quantitative prediction of fetal plasma concentration of fluvoxamine during dosage-tapering to the mother. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28962699/),h,10,227411,DB00715,Paroxetine
,18043911,areas under the concentration-time curve (AUC),"Following the administration of paroxetine, mean metoprolol areas under the concentration-time curve (AUC) increased (1064 +/- 1213 to 4476 +/- 2821 nM x h/mg per kg, P = 0.0001), while metabolite AUCs decreased (1492 +/- 872 to 348 +/- 279 n M x h/mg per kg, P < 0.0001), with an increase of metabolic ratios (MR) (0.9 +/- 1.3 to 26 +/- 29; P < 0.0001).",Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043911/),[h·nM] / [kg·mg],1064,229786,DB00715,Paroxetine
,18043911,areas under the concentration-time curve (AUC),"Following the administration of paroxetine, mean metoprolol areas under the concentration-time curve (AUC) increased (1064 +/- 1213 to 4476 +/- 2821 nM x h/mg per kg, P = 0.0001), while metabolite AUCs decreased (1492 +/- 872 to 348 +/- 279 n M x h/mg per kg, P < 0.0001), with an increase of metabolic ratios (MR) (0.9 +/- 1.3 to 26 +/- 29; P < 0.0001).",Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043911/),[h·nM] / [kg·mg],4476,229787,DB00715,Paroxetine
,18043911,AUCs,"Following the administration of paroxetine, mean metoprolol areas under the concentration-time curve (AUC) increased (1064 +/- 1213 to 4476 +/- 2821 nM x h/mg per kg, P = 0.0001), while metabolite AUCs decreased (1492 +/- 872 to 348 +/- 279 n M x h/mg per kg, P < 0.0001), with an increase of metabolic ratios (MR) (0.9 +/- 1.3 to 26 +/- 29; P < 0.0001).",Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043911/),[M·h·n] / [kg·mg],1492,229788,DB00715,Paroxetine
,18043911,AUCs,"Following the administration of paroxetine, mean metoprolol areas under the concentration-time curve (AUC) increased (1064 +/- 1213 to 4476 +/- 2821 nM x h/mg per kg, P = 0.0001), while metabolite AUCs decreased (1492 +/- 872 to 348 +/- 279 n M x h/mg per kg, P < 0.0001), with an increase of metabolic ratios (MR) (0.9 +/- 1.3 to 26 +/- 29; P < 0.0001).",Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043911/),[M·h·n] / [kg·mg],348,229789,DB00715,Paroxetine
,18043911,metabolic ratios (MR),"Following the administration of paroxetine, mean metoprolol areas under the concentration-time curve (AUC) increased (1064 +/- 1213 to 4476 +/- 2821 nM x h/mg per kg, P = 0.0001), while metabolite AUCs decreased (1492 +/- 872 to 348 +/- 279 n M x h/mg per kg, P < 0.0001), with an increase of metabolic ratios (MR) (0.9 +/- 1.3 to 26 +/- 29; P < 0.0001).",Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043911/),,0.9,229790,DB00715,Paroxetine
,18043911,metabolic ratios (MR),"Following the administration of paroxetine, mean metoprolol areas under the concentration-time curve (AUC) increased (1064 +/- 1213 to 4476 +/- 2821 nM x h/mg per kg, P = 0.0001), while metabolite AUCs decreased (1492 +/- 872 to 348 +/- 279 n M x h/mg per kg, P < 0.0001), with an increase of metabolic ratios (MR) (0.9 +/- 1.3 to 26 +/- 29; P < 0.0001).",Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043911/),,26,229791,DB00715,Paroxetine
,18043911,area under the HR versus time curve (AUEC),Mean area under the HR versus time curve (AUEC) decreased (835 +/- 88 to 728 +/- 84 beats x h/min; P = 0.0007).,Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043911/),[beats·h] / [min],835,229792,DB00715,Paroxetine
,18043911,area under the HR versus time curve (AUEC),Mean area under the HR versus time curve (AUEC) decreased (835 +/- 88 to 728 +/- 84 beats x h/min; P = 0.0007).,Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043911/),[beats·h] / [min],728,229793,DB00715,Paroxetine
,32060866,clearance,"After yohimbine 5 mg, the clearance ranged from 25.3 to 15,864 mL/min and after yohimbine 50 µg, the clearance ranged from 39.6 to 38,822 mL/min.",Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32060866/),[ml] / [min],"25.3 to 15,864",234197,DB00715,Paroxetine
,32060866,clearance,"After yohimbine 5 mg, the clearance ranged from 25.3 to 15,864 mL/min and after yohimbine 50 µg, the clearance ranged from 39.6 to 38,822 mL/min.",Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32060866/),[ml] / [min],"39.6 to 38,822",234198,DB00715,Paroxetine
,10434486,half-life,The mean half-life of paroxetine was 11.1 +/- 5.2 (SD) hours.,Paroxetine pharmacokinetics in depressed children and adolescents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10434486/),h,11.1,247516,DB00715,Paroxetine
,10434486,clearance,The average clearance was 88.7 +/- 66.4 mL/min/kg.,Paroxetine pharmacokinetics in depressed children and adolescents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10434486/),[ml] / [kg·min],88.7,247517,DB00715,Paroxetine
,10434486,area under the plasma drug concentration curve,The mean area under the plasma drug concentration curve was 0.09 +/- 0.10 microgram/mL.hr.,Paroxetine pharmacokinetics in depressed children and adolescents. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10434486/),[μg] / [h·ml],0.09,247518,DB00715,Paroxetine
,23337629,percentage entrapment efficiency (%EE),"Liposomes showed percentage entrapment efficiency (%EE) of 81.22 ± 3.08% for optimized formula (F5) which composed of (LPC:CHOL, 7:7) and 20mg of PAX, with average vesicle size of 220.53 ± 0.757 nm.",Transdermal drug delivery of paroxetine through lipid-vesicular formulation to augment its bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23337629/),%,81.22,252780,DB00715,Paroxetine
,23337629,C(max),"Pharmacokinetic parameters were determined as the C(max) of PAX liposomal transdermal patch was found to be 92.53 ng/ml at t(max) of 12h and AUC(0-48) was 2305.656 ngh/ml and AUC(0-∞) was 3852.726 ngh/ml, compared to the C(max) of 172.35 ng/ml after oral administration of the marketed PAX tablet with t(max) of 6h and AUC(0-24) was 1206.63 ngh/ml and AUC(0-∞) was 1322.878 ngh/ml.",Transdermal drug delivery of paroxetine through lipid-vesicular formulation to augment its bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23337629/),[ng] / [ml],92.53,252781,DB00715,Paroxetine
,23337629,t(max),"Pharmacokinetic parameters were determined as the C(max) of PAX liposomal transdermal patch was found to be 92.53 ng/ml at t(max) of 12h and AUC(0-48) was 2305.656 ngh/ml and AUC(0-∞) was 3852.726 ngh/ml, compared to the C(max) of 172.35 ng/ml after oral administration of the marketed PAX tablet with t(max) of 6h and AUC(0-24) was 1206.63 ngh/ml and AUC(0-∞) was 1322.878 ngh/ml.",Transdermal drug delivery of paroxetine through lipid-vesicular formulation to augment its bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23337629/),h,12,252782,DB00715,Paroxetine
,23337629,AUC(0-48),"Pharmacokinetic parameters were determined as the C(max) of PAX liposomal transdermal patch was found to be 92.53 ng/ml at t(max) of 12h and AUC(0-48) was 2305.656 ngh/ml and AUC(0-∞) was 3852.726 ngh/ml, compared to the C(max) of 172.35 ng/ml after oral administration of the marketed PAX tablet with t(max) of 6h and AUC(0-24) was 1206.63 ngh/ml and AUC(0-∞) was 1322.878 ngh/ml.",Transdermal drug delivery of paroxetine through lipid-vesicular formulation to augment its bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23337629/),[ngh] / [ml],2305.656,252783,DB00715,Paroxetine
,23337629,AUC(0-∞),"Pharmacokinetic parameters were determined as the C(max) of PAX liposomal transdermal patch was found to be 92.53 ng/ml at t(max) of 12h and AUC(0-48) was 2305.656 ngh/ml and AUC(0-∞) was 3852.726 ngh/ml, compared to the C(max) of 172.35 ng/ml after oral administration of the marketed PAX tablet with t(max) of 6h and AUC(0-24) was 1206.63 ngh/ml and AUC(0-∞) was 1322.878 ngh/ml.",Transdermal drug delivery of paroxetine through lipid-vesicular formulation to augment its bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23337629/),[ngh] / [ml],3852.726,252784,DB00715,Paroxetine
,23337629,C(max),"Pharmacokinetic parameters were determined as the C(max) of PAX liposomal transdermal patch was found to be 92.53 ng/ml at t(max) of 12h and AUC(0-48) was 2305.656 ngh/ml and AUC(0-∞) was 3852.726 ngh/ml, compared to the C(max) of 172.35 ng/ml after oral administration of the marketed PAX tablet with t(max) of 6h and AUC(0-24) was 1206.63 ngh/ml and AUC(0-∞) was 1322.878 ngh/ml.",Transdermal drug delivery of paroxetine through lipid-vesicular formulation to augment its bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23337629/),[ng] / [ml],172.35,252785,DB00715,Paroxetine
,23337629,t(max),"Pharmacokinetic parameters were determined as the C(max) of PAX liposomal transdermal patch was found to be 92.53 ng/ml at t(max) of 12h and AUC(0-48) was 2305.656 ngh/ml and AUC(0-∞) was 3852.726 ngh/ml, compared to the C(max) of 172.35 ng/ml after oral administration of the marketed PAX tablet with t(max) of 6h and AUC(0-24) was 1206.63 ngh/ml and AUC(0-∞) was 1322.878 ngh/ml.",Transdermal drug delivery of paroxetine through lipid-vesicular formulation to augment its bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23337629/),h,6,252786,DB00715,Paroxetine
,23337629,AUC(0-24),"Pharmacokinetic parameters were determined as the C(max) of PAX liposomal transdermal patch was found to be 92.53 ng/ml at t(max) of 12h and AUC(0-48) was 2305.656 ngh/ml and AUC(0-∞) was 3852.726 ngh/ml, compared to the C(max) of 172.35 ng/ml after oral administration of the marketed PAX tablet with t(max) of 6h and AUC(0-24) was 1206.63 ngh/ml and AUC(0-∞) was 1322.878 ngh/ml.",Transdermal drug delivery of paroxetine through lipid-vesicular formulation to augment its bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23337629/),[ngh] / [ml],1206.63,252787,DB00715,Paroxetine
,23337629,AUC(0-∞),"Pharmacokinetic parameters were determined as the C(max) of PAX liposomal transdermal patch was found to be 92.53 ng/ml at t(max) of 12h and AUC(0-48) was 2305.656 ngh/ml and AUC(0-∞) was 3852.726 ngh/ml, compared to the C(max) of 172.35 ng/ml after oral administration of the marketed PAX tablet with t(max) of 6h and AUC(0-24) was 1206.63 ngh/ml and AUC(0-∞) was 1322.878 ngh/ml.",Transdermal drug delivery of paroxetine through lipid-vesicular formulation to augment its bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23337629/),[ngh] / [ml],1322.878,252788,DB00715,Paroxetine
,18257133,recovery,The recovery of RIS from serum was in the range of 70.20% approximately 84.50%.,Determination of risperidone in human plasma by HPLC-MS/MS and its application to a pharmacokinetic study in Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18257133/),%,70.20,256036,DB00715,Paroxetine
,18257133,recovery,The recovery of RIS from serum was in the range of 70.20% approximately 84.50%.,Determination of risperidone in human plasma by HPLC-MS/MS and its application to a pharmacokinetic study in Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18257133/),%,84.50,256037,DB00715,Paroxetine
,31268632,Ratio of,We obtained good predictions for the dextromethorphan-duloxetine interaction (Ratio of predicted over observed area under the curve (AUC) ratio (Rpred/obs ) 1.38-1.43).,Physiologically-Based Pharmacokinetic Modeling for the Prediction of CYP2D6-Mediated Gene-Drug-Drug Interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31268632/),,1.38-1.43,257178,DB00715,Paroxetine
,31268632,area under the curve (AU,We obtained good predictions for the dextromethorphan-duloxetine interaction (Ratio of predicted over observed area under the curve (AUC) ratio (Rpred/obs ) 1.38-1.43).,Physiologically-Based Pharmacokinetic Modeling for the Prediction of CYP2D6-Mediated Gene-Drug-Drug Interactions. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31268632/),,1.38-1.43,257179,DB00715,Paroxetine
,31268632,Rpred/obs,"Despite an approximately twofold underprediction of the dextromethorphan-paroxetine interaction, an Rpred/obs of 0.71 was obtained for the effect of genotype on the area under the curve ratio.",Physiologically-Based Pharmacokinetic Modeling for the Prediction of CYP2D6-Mediated Gene-Drug-Drug Interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31268632/),,0.71,257180,DB00715,Paroxetine
,6217723,Plasma half-lives,Plasma half-lives were longer after oral (19.8 hrs. S.D. 1.3 hrs) than after intravenous test (12.3 hrs. S.D. 3.8 hrs).,Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6217723/),h,19.8,269768,DB00715,Paroxetine
,6217723,Plasma half-lives,Plasma half-lives were longer after oral (19.8 hrs. S.D. 1.3 hrs) than after intravenous test (12.3 hrs. S.D. 3.8 hrs).,Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6217723/),h,12.3,269769,DB00715,Paroxetine
,7963446,elimination half-life (t1/2),"Sertraline, and the starting dose of paroxetine have an elimination half-life (t1/2) of approximately 24 h.","Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7963446/),h,24,270767,DB00715,Paroxetine
,7963446,t1/2,At t1/2 of 24 h makes once-daily dosing feasible and allows for new steady-state concentrations and wash-out within a reasonable time after dose adjustment.,"Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7963446/),h,24,270768,DB00715,Paroxetine
,7963446,t1/2,Fluoxetine has a t1/2 of 2-4 days and has an active metabolite with a t1/2 of 7-15 days.,"Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7963446/),d,2-4,270769,DB00715,Paroxetine
,7963446,t1/2,Fluoxetine has a t1/2 of 2-4 days and has an active metabolite with a t1/2 of 7-15 days.,"Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7963446/),d,7-15,270770,DB00715,Paroxetine
